Skip to main content
Download PDF

Prevention of tumor risk associated with the reprogramming of human pluripotent stem cells

Journal of Experimental & Clinical Cancer Research volume 39, Article number: 100 (2020) Cite this article

Abstract

Human pluripotent embryonic stem cells have two special features: self-renewal and pluripotency. It is important to understand the properties of pluripotent stem cells and reprogrammed stem cells. One of the major problems is the risk of reprogrammed stem cells developing into tumors. To understand the process of differentiation through which stem cells develop into cancer cells, investigators have attempted to identify the key factors that generate tumors in humans. The most effective method for the prevention of tumorigenesis is the exclusion of cancer cells during cell reprogramming. The risk of cancer formation is dependent on mutations of oncogenes and tumor suppressor genes during the conversion of stem cells to cancer cells and on the environmental effects of pluripotent stem cells. Dissecting the processes of epigenetic regulation and chromatin regulation may be helpful for achieving correct cell reprogramming without inducing tumor formation and for developing new drugs for cancer treatment. This review focuses on the risk of tumor formation by human pluripotent stem cells, and on the possible treatment options if it occurs. Potential new techniques that target epigenetic processes and chromatin regulation provide opportunities for human cancer modeling and clinical applications of regenerative medicine.

Background

The first successful mammalian reprogramming of vegetal cells to totipotent cells using the technology of nuclear transfer generated the cloned sheep “Dolly” [1]. In recent decades, the problems caused by tumorigenesis generated by oocytes (embryos) created by nuclear transfer have been underestimated. The creation of induced pluripotent stem cells (iPSCs) requires the expression of stemness-related genes, such as the combination of Oct4, Sox2, Klf4, and c-Myc (OSKM) and that of Oct4, Sox2, Nanog and Lin28 (OSNL) [2,3,4,5]. Studies of the risk of tumorigenesis and cancerous transformation have considered somatic cell reprogramming in the context of cancer patient-specific reprogramming [2,3,4,5,6,7,8,9,10,11,12].

Stem cells are putative candidates for cancerous transformation given their ability to self-renew and to dedifferentiate, which can lead to the acquisition of both the genetic and epigenetic modifications required for tumorigenesis [13, 14]. The stemness-related transcription factors are expressed in embryonic stem cells (ESCs) and adult stem cells, but they are not generally expressed in adult somatic cells. Abnormal expression of ESC-specific factors has recently been reported in human tumors [15,16,17]. A retrospective study of human patient cohorts has shown that the expression of these factors with survival outcomes in specific tumor types, which suggests that these factors may be useful for assessing patient prognosis [18].

A recent study reported that the clinical expression of the pluripotent factors OCT4, SOX2, and NANOG (OSN) in cancer patients was associated with treatment resistance of lethal cancers [19]. This expression signature was observed in a large cohort of cancers (n = 884), comprising renal (n = 317), bladder (n = 292), and prostate (n = 275) cancers. The rates of triple coexpression of OSN were 93, 86, and 54% in prostate, invasive cancer of bladder, and renal cancer, respectively. The high level of expression of OSN was also related to worse prognosis and shorter survival. The major regulators of stem cell pluripotency correlated well with poor survival and treatment resistance of cancer. .

One study showed the production of induced transformed cancer stem cells (CSCs) from differentiated cells [20]. Another study showed that the reprogramming of cancer cells with abnormal or deleted p53 enhanced the generation of pluripotent CSCs and the frequency of tumorigenesis by these reprogrammed CSCs [21]. A reprogramming method has been applied to several types of tumor cells as a possible trial for suppressing tumorigenesis [22,23,24]. In these studies, some reprogramming factors were delivered to cancerous cells to generate induced pluripotent CSCs (iPCSCs). This method may provide a good model of tumorigenesis and may have therapeutic potential in the prevention of the initiation of carcinogenesis.

In addition to the use of genetic materials to generate pluripotent stem cells, small-molecule compounds that can promote cell reprogramming have also been used to obtain iPSCs. Small molecules that target molecules in signaling pathways, including the inhibition of histone deacetylase (HDAC), Wnt signaling, and transforming growth factor β (TGFβ) can regulate the expression of genes for pluripotent factors, whose expression can lead to the reprogramming of cells [25]. Various molecules that promote cell reprogramming can be used as substitutes for genetic materials. These include recombinant reprogramming factors (e.g., OSKM) modified by a polyarginine [26] and by small-molecule compounds [27,28,29,30,31,32]. However, the use of chemically defined small molecules alone has not yet generated human iPSCs (hiPSCs) [33]. Furthermore, it has not been clarified whether these small-molecule-driven iPSCs have a reduced risk of tumorigenesis after their therapeutic transfer [34].

In this review, we discuss the current understanding of the risk of tumor formation associated with the reprogramming of various human stem cell-like cells and summarize the possible solutions, such as using anticancer treatments and inhibitors to suppress tumorigenesis in iPSCs, CSCs, and their derivatives (Fig. 1). We have excluded a description of the effects of long noncoding RNAs and microRNAs (miRNAs) on reprogramming in detail from this review article [35, 36].

Fig. 1
figure1

Schematic representation of the recycling of autologous patient-specific induced pluripotent stem cells (iPSCs) to cure human diseases. Somatic cells from patients are established as patient-specific iPSCs, which are corrected genetically by repairing the defect and then differentiating the corrected iPSCs into autologous progenitor cells for use in transplantation. To correct a gene mutation in patient-specific iPSCs, the genetic code and epigenetic factors are corrected using gene editing, antisense, ribozymes, and peptide nucleic acid (PNA) or modified nucleic acids, and/or chromatin modification

Full size image

Characteristics of stem cells and tumor cells

ESCs are established from the inner cell mass (ICM) of blastocyst and can differentiate into all types of cells [15, 16]. The ability to produce teratomas in immune-deficient animals is common pluripotent properties of iPSCs and ESCs [1, 3, 37]. Tumors comprise different types of cancer cells, and this contributes to the heterogeneity of tumors [20]. Teratomas are defined as mixed benign tumors that comprise abnormally developed tissues derived from germ cells with normal karyotypes [37]. Teratomas are regarded as posing no direct danger of forming a malignant tumor, although they have the potential to metastasize in response to some interactions with their microenvironment and niches [38]. Substantial number of tumors can be generated by a series of mutations, which can cause uncontrolled cell division. The process of tumorigenesis is specified by alterations in genetic, epigenetic, cellular, and microenvironmental circumstances [20]. Therefore, the risk of tumorigenesis by any stem cell-derived transplants needs to be eliminated before their clinical applications.

Stemness-related transcription factors in stem cells and cancer cells

To understand difference between and similarities in marker genes in CSCs and ESCs, we have summarized the corresponding signals and their characteristics (Table 1) [16, 17, 39].

Table 1 Summary of the characteristics of embryonic stem cells and cancer stem cells according to theirtranscription factors, markers, signaling pathways, RNA,and epigenetic regulators
Full size table

A few examples are described below.

OCT4

Expression of OCT4 is required for the maintenance of ESC characteristics [123]. Oct4-deficient mice do not generate the ICM and thus differentiate into the trophectoderm [123]. In addition, reduced expression of Oct4 in mouse ESC (mESC) caused in the upregulation of trophectoderm genes (e.g., Cdx29), whose overexpression leads to differentiation into the primitive endoderm and mesoderm [124]. Under serum-free culture conditions, the forced expression of Oct4 in ESCs promotes neuronal differentiation [125]. High expression level of OCT4 is related to poor prognosis in bladder cancer [126, 127], prostate cancer [128], medulloblastoma [129], esophageal squamous cell carcinoma [130], leukemia, and cancers of the ovaries, testicles, and pancreas [18].

SOX2

Expression of Sox2 is detected in ICM and extraembryonic ectoderm of preimplantation blastocysts [131]. Sox2-deficient blastocysts cannot generate a pluripotent ICM. Sox2-deficient mESCs differentiate into trophectoderm, and the overexpression of Oct4 can rescue the pluripotency of Sox2-deficient mESCs [132]. These findings suggest that Sox2 is essential to maintain Oct4 expression. Moreover, the synergistic action of Sox2 and Oct4 in Oct-Sox stem cells-enhancers leads to the regulation of various pluripotent genes, including Oct4, Sox2, and Nanog. In contrast, forced expression of Sox2 in ESCs is reported to lead to their differentiation [133, 134]. This effect was reflected by the reduced expression of pluripotency genes Sox2, Oct4, Nanog, Fgf4, and Utf1 [133] and the induced generation of neuroectoderm, mesoderm and trophectoderm [134]. Increased expression of SOX2 correlates with poor prognosis in stage I lung adenocarcinoma [135], esophageal squamous cell carcinoma [136, 137], gastric carcinoma [138,139,140], small-cell lung carcinoma [141,142,143], breast cancer [144], testicular tumors [145], and ovarian carcinoma [146].

KLF4

KLF4 is one of the Krűppel-like transcription factors family that are involved in reprogramming. Klf4 is expressed in mESCs and is repressed during differentiation [147]. The RNA interference against Klf4 led to the differentiation of ESCs [148, 149], whereas the forced expression of KLF4 delays the differentiation, increases the expression of OCT4, and stimulates self-renewal ability [150]. Klf4 with Oct4 and Sox2 induces the expression of Lefty1 [151] and Nanog [152], KLF4 is also a prognostic predictor of colon cancer [153] and head neck squamous cell carcinoma [154], and is also detected in leukemia, myeloma, testis cancer [18], early stage breast cancer [155], nasopharyngeal cancer [156], and oral cancer [157].

Nanog

In the absence of the leukemia inhibitor factor-signal transducer and activator of transcription (LIF-STAT3) pathway, Nanog is required for the maintenance of ESC properties [158, 159]. Chamber et al. found that expression of Nanog was high in Oct4-knockout embryos, whereas its overexpression did not counteract the differentiation program of ESCs induced by Oct4 deletion [159]. In the absence of Nanog, embryos did not produce a pluripotent ICM, but Nanog deficient mESCs could be established [158, 160]. Nanog downregulation in human ESCs promotes differentiation toward the extraembryonic lineage, as demonstrated by the forced expression of endodermal and trophectodermal specific genes. OCT4–SOX2 heterodimer complex binds to the Octamer–Sox cis-elements in the proximal promoter of NANOG gene and regulate NANOG expression in ESCs [161]. Moreover, Nanog, Oct4, and Sox 2 cooperate with the signaling pathway mediators, which means that signals are delivered directly to the genes regulated by the core factors [162]. Higher expression of NANOG is concerned with poor prognosis for testicular cancer [163], colorectal cancer [164], gastric cancer [140], non-small cell lung carcinoma [165, 166], ovarian cancer [167], and liver cancer [168].

C-Myc

c-Myc is one of the factors for stem cell pluripotency, proliferation, and apoptosis [169,170,171]. c-Myc is directly regulated by LIF-STAT3 signaling, and its constitutive expression renders ESC self-renewal independent of LIF. However, the forced expression of dominant-negative c-Myc induces differentiation [172]. It has been reported that c-Myc represses signaling of the mitogen-activated protein kinase (MAPK) pathway, which led to the inhibition of differentiation [173]. c-Myc binds and regulates the transcription of at least 8000 genes in ESCs including those for E2F–Max complexes, and NuA4 HAT complex, which regulate ESC pluripotency [174]. c-Myc was one of the most important leukemia stemness factors. C-MYC overexpression is found in over 70% of human cancers, including breast cancer, colon cancer, glioma, medulloblastoma, pancreatic cancer, and prostate cancer [18, 175]. c-MYC expression correlates with poor prognosis for hepatocellular carcinoma [176] and early carcinoma of the uterine cervix [177, 178]. c-MYC-driven reprogramming is controlled by the activation of c-MYC-mediated oncogenic enhancers in human mammary epithelial cells [179].

p53

The inhibition of the tumor suppressor protein 53 (TP53) increases the rate of reprogramming of fibroblasts to iPSCs [180, 181], which can differentiate into dopaminergic neurons directly from human fibroblasts [182].

JDP2

The c-Jun dimerization protein 2 (JDP2) is a member of the AP-1/ATF family of transcription factors and can function as a histone chaperone that regulates transcription [183,184,185]. JDP2 is a reprogramming factor because it can regulate the Wnt signaling and function as a suppressor of producing reactive oxygen species (ROS) [186,187,188,189]. For example, addition of the ROS scavenger vitamin C to the culture medium significantly increases the reprogramming efficiency of cultured cells [190]. Activation of the Wnt signaling can maintain the ability for pluripotency in ESCs [41, 191,192,193,194]. ESCs can differentiate into all types of cells, except for some in extraembryonic tissues [37, 38]. The cell reprogramming method that uses OCT4 and JDP2 to generate gastric cancer cells is based on this notion [195]. In that study, reprogramming using these two factors inhibited the tumorigenic function of gastric cancer cells by inhibiting bone morphogenetic protein 7 (BMP7). Moreover, reprogrammed gastric CSC-like cells induced a lower level of tumor formation in immune-deficient mice than did the parental cancer cells [195]. This method is a good example of a therapeutic strategy that might restrict cancer progression by using JDP2 together with OCT4 as reprogramming factors. Collectively, accumulating evidence suggests that ESCs and CSCs share major transcription factors.

Surface markers for stemness in CSCs

The uncontrolled proliferation of many tumors is driven by a small population of cancer cells, known as CSCs, which exhibit the capacity for self-renewal and pluripotency. Unlike somatic cancer cells, CSCs can produce an obvious cancer and propagate the malignant cancerous clones indefinitely. Like the stemness-related transcription factors, surface markers that are expressed in stem cells are also expressed in human cancers. These include TRA-1-60, Stage specific embryonic antigen-1(SSEA-1), Epithelial cell adhesion molecule (EpCAM), Aldehyde dehydrogenase 1 family, member A1 (ALDH1A1), Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5), CD13, CD19, CD20, CD24, CD27, CD34, CD44, CD45, CD47, CD49f, CD66c, CD90, CD166, TNFRSF16, CD105, CD133, c-Kit, CD138, CD151, and CD166. Table 1 shows the surface markers of CSCs, some of which are targets of therapeutics in cancer treatment.

CD133

CD133 is a transmembrane glycoprotein that localizes to cellular protrusions. It is originally known as a stem cell marker which is detected in neuroepithelial stem cells [196] and has been recognized as a CSC marker [197]. This molecule is used to identify many different types of CSCs, including those originating from glioma [198], and colorectal [199, 200], lung [201], liver [202], and prostate [203] cancers. CD133 has been shown to be involved in the regulation of glucose uptake and glucosamine production under condition of high-glucose, circumstances related to glycolysis, and autophagy [204]. However, knockdown of CD133 has no significant effect on cancer development [205]. Both CD133+ and CD133– metastatic colon cancer cells are initiated equally during the early stage of tumor formation [206], which indicates that CD133 expression is not specific and not restricted to stem cells. Therefore, CD133 seems to reflect glucose availability and is not a specific marker of CSCs.

CD44

CD44 is another transmembrane glycoprotein. CD44 is concerned with cell division, migration, and adhesion via different signaling [207]. It is expressed in both normal fetal and adult hematopoietic stem cells. Upon binding to hyaluronic acid (HA), its primary ligand, CD44 mediates cell-cell communication and signal transaction. HA binding to CD44 on cell surface molecules, such as selectin, collagen, osteopontin, fibronectin, and laminin, activates the epidermal growth factor receptor tyrosine kinase and increases cell proliferation and survival through the signals of MAPK and phosphatidylinositol-3-kinase (PI3K)-Akt pathways [208, 209]. Knockdown of CD44 prevents the tumors occurrence induced by colorectal CSCs [205]. CD44 plays a role in in the invasive and tumorigenic abilities with stemness features of several tumor cell types, including breast [210, 211], prostate [212, 213], colon [214, 215], and pancreas [216] cancers, and head and neck squamous carcinoma [217]. Therefore, CD44 is not specific for CSCs but is more of a marker of invasive or metastatic cells. Several other CSC surface markers appear to function in specific types of tumors.

ABCG2

ABCG2 is one of the ATP-binding cassette transporter (ABC) family. ABCG2 may be a universal biomarker of stem cells [16]. ABCG2 plays a vital role in stimulating the proliferation of stem cells and, in the case of esophageal squamous carcinoma, has been shown to be required for the maintenance of the stem cell phenotype [218]. The sensitivity of hepatocarcinoma cells to the chemotherapeutic drugs, doxorubicin and 5-fluorouracil, correlates inversely with the surface levels of AGCG2. The AGCG2 level expressed on cancer cells, including colon cancer lines, also correlates closely with tumorigenicity, drug resistance, proliferation, and metastatic ability [219, 220].

CD13

CD13 encodes the enzyme aminopeptidase N, a Zn2 + −dependent membrane-bound ectopeptidase. CD13 is overexpressed in multiple cancers, including hepatocarcinoma [221], and colon cancer [222], as well as on the surface of vasculature endothelial cells in tumors undergoing angiogenesis [223].

Lgr5

Lgr5 is one of the leucine-rich repeat-containing G-protein-coupled receptor (GPR49) family, which belongs to the seven-transmembrane G-protein-coupled receptor super family. Lgr1 ~ 5 family members are regulatory receptors involved in Wnt signaling [224]. Lgr5 binds to the furin-like repeat domains of R-spondin 1 ~ 4 (RSPO1 ~ 4) to potentiate WNT signaling [225]. However, RSPO1–Lgr5 can also directly activate TGFβ signaling in a cooperative interaction with the TGFβ type II receptor on colon cancer cells, which increases growth inhibition and apoptosis [226]. The effect of Lgr5 expression depends on its interactions with the both Wnt and TGFβ signaling systems [227]. Lgr5 is expressed in many organs including the brain, mammary glands, intestinal tract, stomach, hair follicles, eyes, and reproductive organs [226]. Lgr5 is also a Wnt signaling target. Its expression I increased in prostaglandin E2 (PGE2)-treated colorectal cancer cell lines, but Lgr5 knockdown inhibits the PGE2 survival response and increases cell death [224]. Lgr5 seems to be a global marker of adult stem cells, such as those found in the hair follicles, intestine, liver, colon, rectum, and ovaries [228], and a definitive surface marker of colorectal CSCs that is coexpressed with CD44 and EpCAM [229].

CD326 (EpCAM)

The surface marker EpCAM is a type I transmembrane glycoprotein that acts as a calcium-independent homophilic adhesion receptor with a molecular weight 30–40 kDa. EpCAM is expressed in epithelial tissues, progenitor cells, cancer cells, and stem and germ cells [230]. EpCAM can be downregulated when cancer cells undergo the epithelial-mesenchymal transition (EMT). The wide distribution of EpCAM expression on most cancer cells indicates that it is not a specific marker of CSCs [231].

Stemness-related signaling pathways

Three processes such as maintenance, self-renewal, and differentiation are concerned with embryonic development and homeostasis of adult tissues. Cancers commonly exhibit aberrant functions within these pathways, often in a cell context-dependent manner. Here we discuss the current evidence for the control of the Hedghog (Hh), Notch, LIF-JAK-STAT, PI3K-Akt-mammalian target of rapamycin (mTOR) and Wnt/β-Catenin pathways in CSCs.

Hh signaling

The Hh ligands (Desert hedgehog, Sonic hedgehog, and Indian hedgehog) bind to Patched, which activates downstream signals that lead to the nuclear localization of transcription factors, followed by the upregulation of genes involved in survival, proliferation, and angiogenesis [232]. Hh is the major regulator of vertebrate embryo development, stem cell maintenance, cell growth and differentiation, tissue polarity, cell proliferation, and the EMT [233]. Hh signaling is implicated in CSC self-renewal and cell-fate determination [232] and is considered as a potential therapeutic target in the treatment of breast cancer and pancreatic cancers [234].

Notch signaling

Notch is controlled with cell–cell communication through transmembrane receptors and ligands. In human ESCs, Notch signaling governs the cell-fate determination in the developing embryos and is required for the development of all three germ layers from undifferentiated ESCs [235]. In CSCs, Notch controls tumor immunity and CSC maintenance [59]. Notch signaling is frequently dysregulated in cancers, which provides a survival advantage for tumors and a potential target in the treatment of cancers [236].

LIF–JAK–STAT signaling

LIF–JAK–STAT signaling governs the cell-fate determination, is important in cytokine-mediated immune responses, and is involved in many biological processes such as proliferation, apoptosis, migration, and stem cell regulation [237]. Tight control of JAK–STAT signaling is required for maintenance of stem cells, self-renewal, and anchoring of stem cells in their respective niches by through the regulation of different adhesion molecules.

PI3K–Akt–mTOR signaling

PI3K–Akt–mTOR signaling is crucial to stem cell proliferation, metabolism, and differentiation. This pathway may dysregulate in human cancers [238]. Over 70% of ovarian cancer cells is reported to activate PI3K–Akt–mTOR pathway. This pathway is a therapeutic target in the treatment of this cancer type [74] as well as for neuroblastoma [239], endometrial cancer [239], and acute myeloid leukemia [240].

Wnt–βcatenin signaling

Wnt signaling plays a role in the stem cell differentiation, and dysregulation of Wnt signaling is associated with the expansion of stem and/or progenitor cells, as well as carcinogenesis [241], Targeting of Wnt is one treatment option for hematological malignancies [242], liver cancer [243], and other types of tumors [244].

Mutation of the genome

The first event that triggers the transformation of normal cells into abnormal cells is mutation of the genome. Such mutations may be maintained, and other events, such as changes in the epigenome of stemness-related genes, oncogenes, and tumor suppressor genes, can also trigger the transformation into abnormal cells.

In general, “driver” mutations occur during the initiation stage of cancer and are followed by the accumulation of “passenger” mutations and tumorigenesis [245, 246]. Driver mutations trigger the growth and development of cancers, whereas passenger mutations do not affect clonality [247,248,249]. Recent progress in the technology of deep sequencing has led to identify these mutations in particular oncogenes and/or tumor suppressor genes [250]. However, whether these mutations can become a barrier to the reprogramming of cancer cells remains unclear. Moreover, the reprogramming of cancer cells may induce genomic changes, including chromosomal aberrations, copy number variations (CNVs), and single-nucleotide variations. For example, chromosome abbreviations at trisomy 12, chromosome 8, and chromosome X have been found in ESCs and iPSCs [251,252,253,254,255,256]. CNVs have been detected during reprogramming or mosaicism from parental cells. In some cases, CNVs are also lost by passaging of cells [254, 257,258,259,260].

Single-nucleotide mutations have been analyzed using high-throughput next-generation sequencing technologies [261, 262]. Additional investigation is required to characterize the occurrence of these mutations during cell reprogramming. Mutations in mitochondrial DNA in human iPSCs increase with age, and the use of young donor cells may be one option to overcome this problem [263, 264].

Epigenetic alterations

The oncogenic potential of reprogrammed stem cells correlates with epigenetic and genomic instability [265, 266]. Epigenetic instability during cancer progression can lead to commitment to altered gene expression. Tumor generation can be caused by epigenetic reprogramming such as carcinogenic enhancer reactivation in both somatic and cancer cells [267,268,269]. In general, DNA methylation can silence the expression of the tumor suppressor genes that are required for sustaining normal function, whereas aberrant expression of oncogenes can lead to cancer initiation [270,271,272]. Intriguingly, iPSCs generated from human sarcoma cell lines have the same methylation and demethylation status in the promoters of oncogenes and tumor suppressor genes in the initial stages. In some cases, iPSCs can suppress the oncogenic promoters and maintain the activity of the promoter of tumor suppressor genes. These finding suggest that stem cell factors can inhibit the expression of cancer phenotypes, perturb epigenetics, and change cancer-related gene expression [266].

The factors that regulate chromatin are another possible target for circumventing the cancer risk during cellular reprogramming. Histone modification, noncoding RNA alteration, and chromatin alteration around mutated regions of DNA are key events that change oncogenic features [273]. Moreover, recent evidence of super-enhancers, locus control regions, and phase separation has provided new targets for next-generation reprogramming, to limit the oncogenic risk associated with cell reprogramming [273,274,275]. The methodologies chosen to induce these epigenetic and chromatin changes require careful consideration.

Epigenetic modifiers and cancer cell plasticity

The differences between CSCs and adult stem cells in the early stage are reflected in differences in stemness signals, such as BMP, notch receptor 1 (Notch 1), sonic hedgehog (Shh) signaling molecule, TGFβ, and the wingless-type MMTV integration site family (Wnt). Later, EMT factors such as HIFs, the zinc-finger protein SNAI2 (Slug), the zinc finger protein SNAI1 (Snail), the class A basic helix–loop–helix protein 38 (Twist 1), and the zinc-finger E-box-binding homeobox 1/2 (Zeb 1/2) are activated, which leads to changes in epigenetic signatures during progression. Changes in the epigenetic machinery might be crucial for the acquisition of stemness characteristics by, and the tumorigenesis of CSCs [276].

The epigenetic barriers that determine cell plasticity must be overcome during the initial steps of cell reprogramming. In the first step, DNA methylation by DNA methyltransferases (DNMTs) occurs at CpG islands and is reversed by ten-eleven translocation proteins (TETs), followed by transcriptional silencing. Both DNMTs and TETs affect transcriptional initiation, elongation, splicing, and stability at the CpG-poor and repeat-rich intergenic loci of target genes [277]. Some methylated DNA-specific binding proteins also perform similar functions. In the second step, histone modifications, such as methylation, acetylation, ubiquitination, phosphorylation, and SUMOylation, cause changes in nucleosomes. These changes define functional regions such as promoters, enhancers, and insulators, which determine the transcriptional patterns and cell fates. In the third step, histone modifiers are used to control chromatin during transcription, replication, and genome maintenance.

Several histone modifiers can regulate transcription, such as the polycomb repressive complex (PRC) 1 and 2, and the enhancer of zeste homolog 2 (EZH2), which is the catalytic subunit of PRC2 that mediates transcriptional repression by introducing H3K27me3 [278]. By contrast, in glioblastomas, the H3K27M mutation in H3.1 and H3.3 leads to reduced EZH2 activity and a decreased level of H3K27me3, followed by a more primitive stem-like state [279, 280]. Loss of EZH2 function can induce a transcription program for self-renewal and leukemogenesis [281]. Therefore, EZH2 mutation and deregulation of H3K27me3 seem to be linked.

The trithorax group (TrxG) complex is another factor that plays a role in the control of histone methyltransferase (HMT) in mixed-lineage leukemia (MLL) [282]. In this type of leukemia, the MLL fusion protein MLL-AF9, which lacks the catalytic domain, is produced by chromosomal rearrangement. The committed cells can be reprogrammed toward leukemic stem cells and initiate tumorigenesis [283]. MLL oncogenic fusion proteins require the repressive activity of PRC1, which mono-ubiquitinates histone H2A at lysine 119 (H2AK119Ubi) and mediates transcriptional repression in association with PRC2 [283]. BMI-1 in PRC1 is required to abolish tumor suppressor functions and to enhance CSC self-renewal in solid tumors [284]. Finally, ATP-dependent chromatin modeling complexes that move, eject, or restructure chromatin, are also key elements in the control of tumorigenesis.

Four subfamilies are involved in chromatin remodeling in tumor cells, such as switch/sucrose nonfermentable (SWI/SNF), imitation switch, chromodomain helicase DNA binding protein 1, and INO80 complex ATPase subunit. These differ in their functions, protein domains, and subunit constituents [285]. Loss of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1, a subunit component of the SWI/SNF complex, results in genetic changes that drive rhabdoid tumors and are associated with the inhibition of differentiation, which leads to reprogramming toward oncogenic transcription for oncogenic signaling [286, 287]. The AT-rich interactive domain-containing protein 1A, another subunit of the SWI/SNF complex, functions as a tumor suppressor in colon cancers, and its deletion causes activation of the oncogenic transcriptional program for the promotion of invasive colon adenocarcinoma [288]. These data indicate that epigenetic modifiers also play a critical role in determining stemness/pluripotency and tumorigenesis.

Reversible epigenetic changes play a critical role in the fate decision in cancer cells, which can favor or disfavor the stem cell program that sustains tumor progression. Similarly, cell reprogramming involving epigenesis in cancer cells can generate iPSCs. Chromatin regulators such as the complex of PGC and TrxG proteins can regulate cancers and reprogramming [289]. In glioblastomas, several PRC and TrxG components play important roles in CSC development and in the plasticity of cancer cells. In adult glioblastoma, overexpressed MLL5 represses the expression of H3.3 in CSCs, which causes local reorganization of chromosomes [290]. The upregulation of MLL5 in non-stem cancer cells induces cell plasticity by inhibiting pro-neural differentiation, thereby eliciting a stem cell-like stage.

Another chromatin modifier, the linker histone variant H1.0, is also critical for the plasticity of cancer cells. Perturbation of H1.0 levels affects self-renewal activity directly and promotes the differentiation of non-stem cancer cells, thus blocking their tumorigenicity in vivo [291]. The plasticity of CSCs can be counteracted by epigenetic barriers that prevent cell reprogramming in vitro, such as the deposition of Suv39h1-associated H3K9me2/3 modifications [292]. An interesting insight into these epigenetic barriers was provided by a comparison of the epigenetics of gene expression between adult cells and CSCs in response to tissue damage [293]. In that report, tissue damage activated the resident stem cells, and CSCs exhibited overactivated stress-dependent enhancers and epigenetic modifications, which altered their cell fate and plasticity. These findings highlight the critical role of the reversibility of changes in the chromatin structure in the determination of the functional properties of CSCs.

Alteration in the microenvironment during tumorigenesis

The tumor microenvironment favors a stress-responsive enhancer, which may induce CSC plasticity. Therefore, the microenvironment and niche seem to be critical for the reprogramming to CSCs and iPSCs. Inflammation is an immune reaction to a pathogen [294], during which the responses of immune cells can lead to oxidative damage of DNA in infected cells. Nuclear factor kB and STAT3 can cause parenchymal cells to produce excess amounts of ROS and reactive nitrogen species, which can induce genomic instability and DNA mutations [295]. Mutations and chromosomal alterations are thought to be associated with tumor progression, which may be potentiated by a chronic inflammatory microenvironment that are damaged by mutations.

During CSCs have developed, CSCs may create their own niche. Cells forming the CSC niche necessary for both the maintenance of CSCs and the generation of factors and tumor-associated cells that maintain CSC properties such as invasion, metastasis, and promotion of angiogenesis [296]. The CSCs niche contains cellular components such as cancer-associated fibroblasts [297], tumor-associated macrophages [298], tumor-associated neutrophils [299], mesenchymal-associated cells [300], and cell-mediated adhesion and soluble factors [301], which played important roles in cell–cell communication.

How to avoid tumorigenesis in human pluripotent stem cells

Tumor suppressor genes are mostly transcription factors that modulate the antiproliferation signals that arrest the consistency of the cell cycle for DNA repair and that prevent mutation during cell division [302,303,304,305,306]. For example, the p53 tumor suppressor gene protein product functions as a transcription factor and a cytoplasmic regulator in cell cycle arrest and apoptosis [306,307,308]. The dysregulation of genes that modulate the cell cycle results in uncontrolled cell division, during which a series of mutations to proto-oncogenes and tumor suppressors are needed before cells transform to cancerous cells [309]. Proto-oncogenes are quiescent counterparts of oncogenes that become oncogenes upon mutation. The modified cells produce more of the gene product and exhibit excessive proliferative ability. Hormones or signal transduction can stimulate oncogenes to promote uncontrolled cell proliferation by changing the regulation of gene transcription [310, 311].

Pluripotent reprogramming factors are overexpressed in various cancers [312, 313]. OCT4 has been reported to be overexpressed in a gastric cell line [18], ovarian carcinoma, pancreatic cancer [18], prostate cancer [314], and bladder cancer [315]. c-MYC is also overexpressed in various cancers [316, 317] and can block differentiation and induce tumor formation in the absence of p53 [318, 319]. These observations indicate that reprogramming factors can act as potential proto-oncogenes in the reprogramming process and emphasize the potential risk of carcinogenesis by stem cell-like cells.

Reprogramming

Reprogramming protocols have been used to inhibit the tumorigenesis induced during reprogramming in studies of various cancer cells [20,21,22]. In these models, one or multiple sets of reprogramming factors are delivered to cancer cells and induced patient specific CSCs are generated. These models can be used to study therapeutic targets in the initial stage of carcinogenesis [20,21,22]. In addition to the genetic methods that are used to generate pluripotent stem cells, some small molecules have been reported to promote cell reprogramming. For example, targeting signaling pathways like the HDAC, Wnt, and TGFβ cascades can regulate the expression of pluripotent stemness genes induce the reprogramming of cells [25]. Various molecules that promote reprogramming can replace genetic methods; these include recombinant reprogramming factors (OSKM) with polyarginine tags [26] and other small molecules [30,31,32,33]. However, chemically defined small molecules that induce reprogramming alone have not been developed for human induced pluripotent stem cells (hiPSCs) [24]. Furthermore, whether small molecule-driven iPSCs can prevent the risk of tumorigenesis when used therapeutically has not been determined. The ability of undifferentiated iPSCs to produce teratomas in grafted cell populations is one of the main concerns of this approach, and the nature of these cells should be clarified genetically. Precise information about these transplantation animal models, inoculated patient-specific iPSCs, and the resultant organoids is needed.

Reversibility of the epigenetic state

The use of clones that have been pre-evaluated as being safe is one possibility for overcoming carcinogenic activity, as demonstrated in neural stem cells (NSCs) [320,321,322]. An antibody against SSEA-5 on human ESCs (hESCs) can be utilized to remove teratoma-forming cells from dissociated hESCs [323]. In immune-deficient mice, flow cytometric analysis has shown that transplants of SSEA-5-negative cells formed smaller teratomas, measuring < 1 cm3, whereas SSEA-5-positive transplanted cells formed teratomas > 1 cm3. Flow cytometric analysis using an anti-SSEA-5 antibody may be useful for separating undifferentiated, unsafe cells from iPSC-driven mixed-cell populations. The induction of senescence generated by replication stress and DNA damage, telomere shortening, environmental and oncogenic stresses, and the pro- inflammation inducing microenvironments is one of the oncogene-associated events involving epigenetic control [285]. Cancer-associated senescence has been reported to promote cancer stemness and plasticity in CSCs [306].

Risk management to prevent tumorigenesis

Three different approaches for the removal of tumor-initiating pluripotent stem cells from ESCs and their differentiated cells have been reported: (i) chemical treatment [324,325,326,327], (ii) genetic treatment [328,329,330], and (iii) immunological treatment [323, 331,332,333,334,335] (Table 2). Each method has its advantages and disadvantages; the latter include the high cost, variation between lots, nonspecific antibody binding, integration of toxic genes, and long duration [354]. A strategy for application to clinics to abate the teratoma formation should be explored further [354, 355]. The use of small molecules has several advantages, such as robustness, efficiency, speed, simplicity, and low cost. Some small molecules can inhibit the formation of teratoma in human pluripotent stem cells (hPSCs). For example, an inhibitor of stearoyl-CoA desaturase (SCD), PluriSIns #1, has been shown to prevent teratoma formation [325]. SCD1 is an important enzyme in the biochemical synthesis of monosaturated fatty acids, which are needed for the survival of hPSCs. A recent study reported that SCDs play a critical role in endoplasmic reticulum (ER) stress and promote the survival of glioblastoma cancer stem cells [356]. The N-benzylnonanamide JC101 induces ER stress via the protein kinase RNA-like endoplasmic reticulum kinase/ATF4/DNA damage inducible transcript 3 (DDIT3 = CHOP) pathway [340], which leads to the inhibition of teratoma formation. In a study that used iPSCs to treat spinal cord injury, these cells were determined to be safe before the grafting of transplants, which prevented the formation of teratomas [357].

Table 2 Summary of the procedures for reprogramming and the targeted functions in human pluripotent stem cells and their derivatives
Full size table

The introduction of inhibitors of antiapoptotic factors that effectively remove residual iPSCs can also prevent teratoma formation [344, 348]. Treatment with survivin (an antiapoptotic factor) and a novel survivin suppressant, YM155, was effective in decreasing the risk of teratoma formation. In that study, addition of YM155 permitted the survival of CD34+ cord blood cells and prevented teratoma formation in human induced pluripotent stem cells (hiPSCs)-grafted mice [347].

The introduction of inducible caspase-9 (iCap9), as a suicide gene, into hiPSCs avoided tumorigenic transformation after their transplantation [347, 348]. The efficiency of iCap9 and small molecule-like chemically induced dimerization (CID) in the prevention of the risk of tumorigenesis was evaluated in cell-transplantation experiments. iCap9 integrated with CID induced the apoptosis of iPSCs and iPSC-derived NSCs and produced the terminal differentiation of transduced cells grafted into injured spinal cord in mice but avoided the formation of teratomas [348].

A conditionally replicating adenovirus that targets cancers using multiple factors (m-CRAs) is a new antitumorigenic agent used in hPSC-based cell therapy. Given that the survivin promoter is stronger in undifferentiated hPSCs than was the telomerase reverse transcriptase (TERT) promoter, surviving promoter m-CRAs efficiently kill undifferentiated hPSCs but not differentiated normal cells when compared with TERT promoter m-CRAs. The surviving promoter m-CRAs seems to be a novel antitumorigenic agent that may facilitate safer hPSC-based medical applications [358].

Another approach is the isolation of the desired differentiated cells from other cell types and undifferentiated hPSCs, such as the removal method of the residual pluripotent cells from other cells using fluorescence-activated cell sorting or antibodies coated magnetic beads against a particular antigen, including SSEA-5 [323], claudin-6 [333, 359], and the Ulex europaeus agglutinin-1 fucose-binding lectin (UEA) [360]. Caludin-6 bound to the enterotoxin produced by Clostridium perfringens kills the hPSCs that induce teratoma formation [333]. Yet another approach is the direct, targeted killing of tumor cells using a cytotoxic antibody against the podocalyxin-like protein-1, an inhibitor of stearoyl-CoA desaturases or a DNA topoisomerase II inhibitor, etc. Etoposide, a DNA topoisomerase II inhibitor, and the CDK inhibitor purvalanol have been used to minimize the risks of tumor formation by post-transplanted ESCs and iPSCs [345, 346]. Lin et al. reported that the cardiac glycosides digoxin and lanatoside C can kill undifferentiated hESCs [339].

Important effects of JDP2 on reprogramming-derived CSCs

The activation of the Wnt signaling is critical for maintaining of pluripotency in ESCs [41, 185, 186, 192, 193]. JDP2, has been used as a pluripotency-promoting factor in the reprogramming of cancer cells to reduce their cancerous features. JDP2 can activate or repress various gene transcription actions [185, 361], although it also plays a critical role in malignant transformation. For example, JDP2 can promote cancer cell growth in leukemia and hepatocellular carcinoma [362, 363] but may also be a tumor suppressor in cancer cells [159, 364]. The treatment of gastric cancer cell lines with OCT4 and JDP2 inhibited the tumorigenic function of the cells by switching off BMP7 [195, 365]. The tumor-forming ability of these partially reprogrammed gastric CSC-like cells is reduced in immune-deficient mice, which shows that JDP2 plays a critical role in the reduction of oncogenic potential [185, 189].

Double deficiency of ATF3 and Jdp2 in mice stromal tumors promotes cancer growth [361]. Jdp2 is regarded as a factor that drives reprogramming through the regulation of the Wnt signaling pathway and the suppression of ROS production [188]. Oxygen regulates pluripotent stem cells via Wnt–β-catenin signaling and HIF-1α [188]. Wnt signaling plays a key role in the generation and maintenance of iPSCs [366]. JDP2 is one of the target genes of the LEF–TCF family and is involved in the Wnt signaling pathway [185]. Wang et al. generated iPSC-like cells by introducing OCT4 and JDP2 (JO) into gastric cancers for reprogramming [306]. ESC-like colonies were obtained in teratomas of JO-introduced xenografts. The JO-introduced xenografts were smaller and had fewer necrotic and mitotic cells, and a larger nucleus, than the parent cancer xenografts.

The roles of EZH2, HMT, and MLL in the regulation of BMP7 expression have been examined [364, 365]. The findings of this study suggest that HMT inhibitors can be used to prevent MLL and that EZH2 is a potential therapeutic target. The β-catenin–JDP2–RPMT5 complex axis is critical for reestablishing glutathione homeostasis after genotoxic-mediated stress and may be useful in the development of drugs aimed at treating or avoiding inducible resistance to chemotherapy in cancer cells [367]. A combination of factors (Jdp2, Jhdm1b, Mkk6, Glis1, Nanog, Essrb, and Sall4) was reported to be a useful reprogramming complex for efficiently leading mouse embryonic fibroblasts (MEFs) to become chimera-competent iPSCs in xenografts [368]. These findings suggest that the direct reprogramming of stem cells cannot reduce the risk of malignancy itself, and that excluding cancer cells from the microenvironment of stem cells may be crucial for reducing the risk of cancer.

Other solutions to eliminate the risk of tumorigenesis

Methods of pluripotency reprogramming that do not use genetic material provide another potential strategy for generating safe iPSCs. To date, various molecules that promote cell reprogramming have been reported as substitutes for genetic materials. These small molecules modulate the activities of the enzymes that are involved in the epigenetic modification of genes and may play a crucial role in pluripotency reprogramming [25, 27,28,29,30, 369]. These small molecules include the TGFβ inhibitory antagonist SB431542, the MAPK–extracellular signal-regulated kinase inhibitor PD0325901, and the inhibitor of Rho-associated coiled-coil-containing protein kinase thiazovivin (2,4-disubstituted thiazole or TZV). TZV significantly increases the rate of hiPSC reprogramming by up to 200-fold [370]. The combination of Oct4, the TGFβ receptor inhibitor A83–01, and the methyltransferase inhibitor AMI-5 increases the reprogramming efficiency of mouse iPSCs, and the repression of ROS increases the efficiency of cell reprogramming [371, 372]. The addition of vitamin C to the culture medium significantly increases the reprogramming efficiency. However, the generation of hiPSCs using small-molecule compounds alone has not been shown to reduce the risk of tumorigenesis significantly. Further investigation of nongenetic compound-guided iPSCs is required to exclude the potential for tumor progression before patient engraftment.

Vitamin C is a candidate for preventing the tumorigenesis caused by hiPSCs because it inhibits the improper self-renewal of human stem cells by increasing histone demethylase activity. Vitanin C has also been applied as an anticancer agent in melanomas [373,374,375,376]. The histone demethylases JIhdm1a/1b are the direct downstream molecules of vitamin C. In addition to its antioxidant activity [376], vitamin C was reported to increase the rate of reprogramming of fibroblasts to iPSCs when added to the culture medium [190]. In that study, supplementation with vitamin C decreased p53/p21 levels, which successfully blocked pluripotency reprogramming.

The mutation frequencies in hiPSCs increases with age. Aging is also one of the major risk factors for cancer progression. Therefore, younger donor cells may be used to avoid detrimental mutations in mitochondrial DNA. The reprogramming of somatic cells into iPSCs resets the cellular damage and the stress- and senescence-associated epigenetic marks in vitro, which suggests that the reprogramming technology may be able to induce the rejuvenation of senescent cells [377]. Mosteiro et al. reported that cells reprogrammed in vitro were present next to senescent cells clustered in reprogrammable mice [378]. These senescent cells promote reprogramming through senescence-associated secretory phenotypes, especially via the production of interleukin 6 [379]. The functional crosstalk between reprogramming and senescence has been reported elsewhere [380, 381].

To avoid the risk of point mutations in stem cells, histocompatibility antigen-matched umbilical cord blood-derived iPSCs are useful for ensuring a minimal rate of mutations [382]. Amniotic cells derived from human placental tissues exhibit lower immunogenicity and anti-inflammatory properties than do other cells [383, 384]. The expression of putative immunosuppressors, such as CD59 and CD73, is repressed during the process of reprogramming in amniotic cells [385]. These findings emphasize that long-term-cultured hESCs and hiPSCs show increased growth rates and decreased dependence on the concentration of growth factors and malignant tumor-forming abilities after their engraftment in mice [386]. Carcinoma-derived iPCSCs, which have a higher number of passages, exhibit increased carcinogenic ability compared with those obtained from donor cholangiocellular carcinoma [387].

Other candidate for therapeutic agents includes drugs against the super-enhancers involved in phase separation [388]. In general, the machinery used for epigenetic modification can be altered during transcription initiation, elongation, and termination by involving the transcriptional complex containing polymerase II. Transcriptional regulators such as the mediator MED, coactivator Brd4, splicing factor SRSF2, histone heterochromatin protein 1, and nucleoplasmin 1 may be targets for therapies aimed at modulating chromatin structure during reprogramming and for blocking the development of cancer or other genetic diseases [389]. Hepatocellular carcinomas (HCCs) exhibit distinct promoter hypermethylation patterns. Deletion of C/EBPβ expression using the CRISPR-Cas9 system affects the co-recruitment of BRD4 at enhancers marked with H3K27ac to block the development of HCC [390].

The two mediator kinases, CDK8 and CDK19, may enable transcriptional reprogramming through the super-enhancer family, chromatin looping by CTCF, and cohesion with the transcriptional mediators MED12 and 13, which may be potential drug targets [391]. The valproic acid-mediated inhibition of HDAC and glycogen synthase kinase-3 results in the transcriptional repression of many genes, including the gene that encodes for myristoylated alanine-rich C-kinase substrate 1, which is the Actin-stabilizing protein that is required for the process of the early development of dendritic morphogenesis and synapse maturation [392]. In zebrafish, p300 and Brd4 trigger genome-wide transcriptional network by controlling histone acetylation of the first zygotic genes. This mechanism is crucial for initiation of zygotic development and reproduction [393]. In mammals, these target genes are also potential candidates for drug targets. Stem cell-derived organoids may also be useful for identifying the effects of the microenvironmental niche on cancer development and the reprogramming fates of stem cells [394].

The successful epigenetic reprogramming of primary cancerous cells was recently reported [350]. Pancreatic ductal adenocarcinoma cells were reprogrammed by independent protocols, such as the introduction of OCT4 together with miRNA of Mir302, the episomal vector-encoded NANOG and REX1, in Yamanaka’s protocol (as a control). These methods yielded efficient reprogramming with reduced tumorigenicity through epigenetic changes, such as downregulation of TET2, SIRT1, disruptor of telomeric silencing 1-like (DOT1L), and T-box 3 (TBX3) and upregulation of TET1. A study of ischemic cardiomyopathy found that DNA methylation and the metabolic pathway were strongly correlated through the EZH2–KLF15 axis [351]. C/EBPβ recruits the DOT1L methyltransferase to open chromatin via methylation of H3K79 in multiple drug-resistance genes [352].

Imprint dysregulation compromises the developmental ability of pluripotent stem cells [353]. The stability of de novo methylation of CpG islands in PSCs is critical for cancer development. Thus, CpG islands and imprinting-control regions are important for the evaluation of development, stemness, and pluripotency [395]. Reprogrammed hiPSCs exhibit greater loss of imprinting compared with ESCs, and the loss of imprinting preexists in their somatic cells of origin. The differently imprinted genes related to the loss of imprinting, especially those of paternal control, are more prone to disruption [396].

Ubiquitin-like with PHD and RING finger domain 1 (Uhrf1) is a hemimethylated DNA-binding protein that interacts with DNMT1 and recruits euchromatic histone–lysine N-methyltransferase 2 to form heterochromatin, together with tripartite motif-containing 28 and HDACs, for DNA methylation. In mouse stem cells, Uhrf1 interacts with the SET domain complex containing 1A/COMPASS, followed by positive regulation of H3K4me3 modification. Uhrf1 maintains bivalent histone marks, such as H3K27me3 and H3K4me3, and particularly those associated with specifications to the neuroectoderm and mesoderm [396]. Tatton-Brown–Rahman syndrome (TBRS) is caused by a mutation in DNMT3A, a gene that is also associated with Sotos syndrome, which is caused by haploinsufficiency of NSD1, an HMT that catalyzes the demethylation of histone H3 at K36 (H3K36m22). In the mouse, NSD1-mediated H3K36me2 methylation is induced by the recruitment of DNMT3A and is crucial for the maintenance of DNA methylation at intergenic regions. The binding of DNMT3A to H3K36me2 can be inhibited by a missense mutation associated with TBRS, which suggests that trans-chromatin regulatory control is critical for human neoplastic and developmental growth [397].

Conclusion

Genetic or epigenetic alterations in proteins or microenvironmental niches might promote the initiation or progression of carcinogenesis in some cells. Further steps should be taken to provide effective anticancer systems for the therapeutic application of reprogramming-guided human stem cells. One intriguing technique is the use of a CRISPR-Cas-derived vector to remove the targeted region of epigenetic barriers to identify the effects of transcriptional reprogramming. Targeting of dCAS9-VP64 to the Sox1 promoter produces strict transcript and protein upregulation in neural progenitor cells. The removal of DNA methylation by dCas9-Tet1 increases the proportion of cells with activating master key transcription factors for abrogating the barriers of cell fate [398]. The single-cell sequencing technique is also critical for defining cell fate and the decision toward differentiation.

The ascorbic acid plus 2i and Dot1l inhibitor drugs can rapidly affect the conversion of MEFs to iPSCs. The stemness gene Nanog appears in a subcluster with genes such as those encoding the epithelial cell adhesion molecule (Epcam), Sal-like protein 4 (Sall4), and thymine DNA glycosylase genes (Tdg). The Tdg tandem duplicate 1 (Tdg1) and Oct4 cluster with Zfp42, and Sox2 clusters with the undifferentiated embryonic cell transcription factor 1 (Utf1) and the developmental pluripotency-associated protein 5A (Dppa5a). Sustained coexpression of Epcam, Nanog, and Sox2 with other genes is also required for progression of MEFs toward iPSCs. The genes for Ets homologous factor (Ehf), pleckstrin homology-like domain family A member 2 (Phlda2), and eukaryotic initiation factor 4A-I (Eif4a1) also play critical roles in robust iPSC generation.

Regulatory network analyses allow the search for new networks of signaling, such as signaling inhibition by 2i, and their role in repressing somatic expression. Such analyses also allow the comparison of the actions of the epigenetic modifier ascorbic acid and a Dot1l inhibitor for pluripotent gene activation [399]. In one study, human iPSC-derived neurospheres were transferred into nonobese diabetic-severe combined immune-deficient mice, to treat and cure a spinal cord injury without any tumor generation [349]. These grafted hiPSC-NSs survived, migrated, and differentiated into functional neurons. However, the direct application of undifferentiated iPSCs or hPSCs to patients has not been reported and further research and advances are needed to generate transplantable stem cells or organoids that can be applied to patients in the near future.

Collectively, the data discussed in this review show that the characteristics of pluripotency can inhibit the features of the cancer phenotype, restore differentiation potential, and change the expression of the indicated cancer-related genes through epigenetic modifications, chromatin organization, and metabolism reprogramming (Table 2). Therefore, the targeting of these epigenetic alterations may provide effective approaches for inhibiting the tumorigenic capability of CSCs in the future. Further study is required to provide further understanding of the molecular machineries underlying the reprogramming of cancer cells and the development of novel therapies for the regenerative reprogramming of human cancer cells and their derived organoids.

Availability of data and materials

Not applicable.

Abbreviations

BMP7:

Bone morphogenetic protein 7

CNVs:

Copy number variations

CSCs:

Cancer stem cell

DNMT:

DNA methyltransferase

EMT:

Epithelial mesenchymal transition

ESCs:

Embryonic stem cells

EZH2:

Enhancer of zesta

HDAC:

Histone deacetylase

hESCs:

Human embryonic stem cells

hiPSCs:

Human induced pluripotent stem cells

iPSCs:

Induced pluripotent stem cells

JDP2:

Jun dimerization protein 2

miRNA:

MicroRNA

OSKM:

Oct4, Sox2, Klf4 and c-Myc

OSNL:

Oct4, Sox2, Nanog, and Lin28

PGE2:

Prostaglandin E2

PRC:

Polycomb repressive complex

PSC:

Pluripotent stem cells

ROS:

Reactive oxygen species

SCD:

stearoyl-CoA desaturase

TERT:

Telomerase reverse transcriptase

TET:

Ten-eleven translocation protein

TGFβ:

Transforming growth factor β

References

  1. 1.

    Campbell KH, McWhir J, Ritchie WA, Wilmut I. Sheep cloned by nuclear transfer from a cultured cell line. Nature. 1996;380(6569):64–6.

    PubMed  Article  CAS  Google Scholar 

  2. 2.

    Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  3. 3.

    Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76.

    Article  CAS  Google Scholar 

  4. 4.

    Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009;324(5928):797–801.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  5. 5.

    Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917–20.

    PubMed  Article  CAS  Google Scholar 

  6. 6.

    Boumahdi S, Driessens G, Lapouge G, Rorive S, Nassar D, Le Mercier M, et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature. 2014;511(7508):246–50.

    PubMed  Article  CAS  Google Scholar 

  7. 7.

    Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem. 2008;283(26):17969–78.

    PubMed  Article  CAS  Google Scholar 

  8. 8.

    Hart AH, Hartley L, Parker K, Ibrahim M, Looijenga LH, Pauchnik M, et al. The pluripotency homeobox gene NANOG is expressed in human germ cell tumors. Cancer. 2005;104(10):2092–8.

    PubMed  Article  CAS  Google Scholar 

  9. 9.

    Hochedlinger K, Yamada Y, Beard C, Jaenisch R. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell. 2005;121(3):465–77.

    PubMed  Article  CAS  Google Scholar 

  10. 10.

    Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448(7151):313–7.

    PubMed  Article  CAS  Google Scholar 

  11. 11.

    Peng S, Maihle NJ, Huang Y. Pluripotency factors Lin28 and Oct4 identify a sub-population of stem cell-like cells in ovarian cancer. Oncogene. 2010;29(14):2153–9.

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Saha K, Jaenisch R. Technical challenges in using human induced pluripotent stem cells to model disease. Cell Stem Cell. 2009;5(6):584–95.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  13. 13.

    Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature. 2009;457(7229):608–U119.

    PubMed  Article  CAS  Google Scholar 

  14. 14.

    Yilmaz A, Benvenisty N. Defining Human Pluripotency. Cell Stem Cell. 2019;25(1):9–22.

    PubMed  Article  CAS  Google Scholar 

  15. 15.

    Monk M, Holding C. Human embryonic genes re-expressed in cancer cells. Oncogene. 2001;20(56):8085–91.

    PubMed  Article  CAS  Google Scholar 

  16. 16.

    Zhao W, Ji X, Zhang F, Li L, Ma L. Embryonic stem cell markers. Molecules. 2012;17(6):6196–236.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  17. 17.

    Zhao W, Li Y, Zhang X. Stemness-Related Markers in Cancer. Cancer Transl Med. 2017;3(3):87–95.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  18. 18.

    Schoenhals M, Kassambara A, De Vos J, Hose D, Moreaux J, Klein B. Embryonic stem cell markers expression in cancers. Biochem Biophys Res Commun. 2009;383(2):157–62.

    PubMed  Article  CAS  Google Scholar 

  19. 19.

    Hepburn AC, Steele RE, Veeratterapillay R, Wilson L, Kounatidou EE, Barnard A, et al. The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance. Oncogene. 2019;38(22):4412–24.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  20. 20.

    Miyoshi N, Ishii H, Nagai K, Hoshino H, Mimori K, Tanaka F, et al. Defined factors induce reprogramming of gastrointestinal cancer cells. Proc Natl Acad Sci U S A. 2010;107(1):40–5.

    PubMed  Article  Google Scholar 

  21. 21.

    Carette JE, Pruszak J, Varadarajan M, Blomen VA, Gokhale S, Camargo FD, et al. Generation of iPSCs from cultured human malignant cells. Blood. 2010;115(20):4039–42.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  22. 22.

    Ramos-Mejia V, Fraga MF, Menendez P. iPSCs from cancer cells: challenges and opportunities. Trends Mol Med. 2012;18(5):245–7.

    PubMed  Article  CAS  Google Scholar 

  23. 23.

    Koren S, Reavie L, Couto JP, De Silva D, Stadler MB, Roloff T, et al. PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature. 2015;525(7567):114–8.

    PubMed  Article  CAS  Google Scholar 

  24. 24.

    Kuo KK, Lee KT, Chen KK, Yang YH, Lin YC, Tsai MH, et al. Positive Feedback Loop of OCT4 and c-JUN Expedites Cancer Stemness in Liver Cancer. Stem Cells. 2016;34(11):2613–24.

    PubMed  Article  CAS  Google Scholar 

  25. 25.

    Hou P, Li Y, Zhang X, Liu C, Guan J, Li H, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science. 2013;341(6146):651–4.

    PubMed  Article  CAS  Google Scholar 

  26. 26.

    Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009;4(5):381–4.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  27. 27.

    Feng B, Ng JH, Heng JC, Ng HH. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell. 2009;4(4):301–12.

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Firestone AJ, Chen JK. Controlling destiny through chemistry: small-molecule regulators of cell fate. ACS Chem Biol. 2010;5(1):15–34.

    PubMed  Article  CAS  Google Scholar 

  29. 29.

    Higuchi A, Ling QD, Kumar SS, Munusamy MA, Alarfaj AA, Chang Y, et al. Generation of pluripotent stem cells without the use of genetic material. Lab Invest J Technical Methods Pathol. 2015;95(1):26–42.

    Article  CAS  Google Scholar 

  30. 30.

    Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE, et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol. 2008;26(7):795–7.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  31. 31.

    Li X, Xu J, Deng H. Small molecule-induced cellular fate reprogramming: promising road leading to Rome. Curr Opin Genet Dev. 2018;52:29–35.

    PubMed  Article  CAS  Google Scholar 

  32. 32.

    Papaccio F, Paino F, Regad T, Papaccio G, Desiderio V, Tirino V. Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development. Stem Cells Transl Med. 2017;6(12):2115–25.

    PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Zhu S, Li W, Zhou H, Wei W, Ambasudhan R, Lin T, et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell. 2010;7(6):651–5.

    PubMed  Article  CAS  Google Scholar 

  34. 34.

    Deng J, Zhang Y, Xie Y, Zhang L, Tang P. Cell Transplantation for Spinal Cord Injury: Tumorigenicity of Induced Pluripotent Stem Cell-Derived Neural Stem/Progenitor Cells. Stem Cells Int. 2018;2018:5653787.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  35. 35.

    Liu H, Luo J, Luan S, He C, Li Z. Long non-coding RNAs involved in cancer metabolic reprogramming. Cell Mol Life Sci. 2019;76(3):495–504.

    PubMed  Article  CAS  Google Scholar 

  36. 36.

    Zhang Z, Zhuang L, Lin CP. Roles of MicroRNAs in Establishing and Modulating Stem Cell Potential. Int J Mol Sci. 2019;20(15):3643.

  37. 37.

    Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292(5819):154–6.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  38. 38.

    Abad M, Mosteiro L, Pantoja C, Canamero M, Rayon T, Ors I, et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature. 2013;502(7471):340–5.

    PubMed  Article  CAS  Google Scholar 

  39. 39.

    Niwa H. The pluripotency transcription factor network at work in reprogramming. Curr Opin Genet Dev. 2014;28:25–31.

    PubMed  Article  CAS  Google Scholar 

  40. 40.

    Niwa H, Burdon T, Chambers I, Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 1998;12(13):2048–60.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  41. 41.

    Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 2004;10(1):55–63.

    PubMed  Article  CAS  Google Scholar 

  42. 42.

    Blauwkamp TA, Nigam S, Ardehali R, Weissman IL, Nusse R. Endogenous Wnt signalling in human embryonic stem cells generates an equilibrium of distinct lineage-specified progenitors. Nat Commun. 2012;3:1070.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  43. 43.

    Qu Q, Sun G, Li W, Yang S, Ye P, Zhao C, et al. Orphan nuclear receptor TLX activates Wnt/beta-catenin signalling to stimulate neural stem cell proliferation and self-renewal. Nat Cell Biol. 2010;12(1):31–40 sup pp 1–9.

    PubMed  Article  CAS  Google Scholar 

  44. 44.

    Lukacs RU, Memarzadeh S, Wu H, Witte ON. Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell. 2010;7(6):682–93.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  45. 45.

    Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2011;481(7379):85–9.

    PubMed  Article  CAS  Google Scholar 

  46. 46.

    Pacheco-Pinedo EC, Durham AC, Stewart KM, Goss AM, Lu MM, Demayo FJ, et al. Wnt/beta-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. J Clin Invest. 2011;121(5):1935–45.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  47. 47.

    Paluszczak J. The Significance of the Dysregulation of Canonical Wnt Signaling in Head and Neck Squamous Cell Carcinomas. Cells. 2020;9(3):723.

  48. 48.

    Heo JS, Lee MY, Han HJ. Sonic hedgehog stimulates mouse embryonic stem cell proliferation by cooperation of Ca2+/protein kinase C and epidermal growth factor receptor as well as Gli1 activation. Stem Cells. 2007;25(12):3069–80.

    PubMed  Article  CAS  Google Scholar 

  49. 49.

    Wu SM, Choo AB, Yap MG, Chan KK. Role of Sonic hedgehog signaling and the expression of its components in human embryonic stem cells. Stem Cell Res. 2010;4(1):38–49.

    PubMed  Article  CAS  Google Scholar 

  50. 50.

    Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Current Biol. 2007;17(2):165–72.

    Article  CAS  Google Scholar 

  51. 51.

    Feldmann G, Dhara S, Fendrich V, Bedja D, Beaty R, Mullendore M, et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 2007;67(5):2187–96.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  52. 52.

    Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66(12):6063–71.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  53. 53.

    Xu Y, Song S, Wang Z, Ajani JA. The role of hedgehog signaling in gastric cancer: molecular mechanisms, clinical potential, and perspective. Cell Commun Signaling. 2019;17(1):157.

    Article  Google Scholar 

  54. 54.

    Lowell S, Benchoua A, Heavey B, Smith AG. Notch promotes neural lineage entry by pluripotent embryonic stem cells. PLoS Biol. 2006;4(5):e121.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  55. 55.

    Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene. 2008;27(38):5124–31.

    PubMed  Article  CAS  Google Scholar 

  56. 56.

    Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006;66(15):7445–52.

    PubMed  Article  CAS  Google Scholar 

  57. 57.

    Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML, et al. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res. 2010;70(4):1469–78.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  58. 58.

    Ayyanan A, Civenni G, Ciarloni L, Morel C, Mueller N, Lefort K, et al. Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism. Proc Natl Acad Sci U S A. 2006;103(10):3799–804.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  59. 59.

    Abel EV, Kim EJ, Wu J, Hynes M, Bednar F, Proctor E, et al. The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer. PLoS One. 2014;9(3):e91983.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  60. 60.

    Ogawa K, Saito A, Matsui H, Suzuki H, Ohtsuka S, Shimosato D, et al. Activin-Nodal signaling is involved in propagation of mouse embryonic stem cells. J Cell Sci. 2007;120(Pt 1):55–65.

    PubMed  CAS  Google Scholar 

  61. 61.

    James D, Levine AJ, Besser D, Hemmati-Brivanlou A. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells. Development. 2005;132(6):1273–82.

    PubMed  Article  CAS  Google Scholar 

  62. 62.

    Schober M, Fuchs E. Tumor-initiating stem cells of squamous cell carcinomas and their control by TGF-beta and integrin/focal adhesion kinase (FAK) signaling. Proc Natl Acad Sci U S A. 2011;108(26):10544–9.

    PubMed  PubMed Central  Article  Google Scholar 

  63. 63.

    Oshimori N, Fuchs E. The harmonies played by TGF-beta in stem cell biology. Cell Stem Cell. 2012;11(6):751–64.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  64. 64.

    Zhang Y, Que J. BMP Signaling in Development, Stem Cells, and Diseases of the Gastrointestinal Tract. Annu Rev Physiol. 2020;82:251–73.

    PubMed  Article  CAS  Google Scholar 

  65. 65.

    Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M, et al. TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest. 2013;123(3):1348–58.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  66. 66.

    Chruscik A, Gopalan V, Lam AK. The clinical and biological roles of transforming growth factor beta in colon cancer stem cells: A systematic review. Eur J Cell Biol. 2018;97(1):15–22.

    PubMed  Article  CAS  Google Scholar 

  67. 67.

    Kunath T, Saba-El-Leil MK, Almousailleakh M, Wray J, Meloche S, Smith A. FGF stimulation of the Erk1/2 signalling cascade triggers transition of pluripotent embryonic stem cells from self-renewal to lineage commitment. Development. 2007;134(16):2895–902.

    PubMed  Article  CAS  Google Scholar 

  68. 68.

    Xu C, Inokuma MS, Denham J, Golds K, Kundu P, Gold JD, et al. Feeder-free growth of undifferentiated human embryonic stem cells. Nat Biotechnol. 2001;19(10):971–4.

    PubMed  Article  CAS  Google Scholar 

  69. 69.

    di Martino E, Tomlinson DC, Knowles MA. A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. Adv Urol. 2012;2012:429213.

    PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65(13):5506–11.

    PubMed  Article  CAS  Google Scholar 

  71. 71.

    Dirks PB. Brain tumor stem cells: bringing order to the chaos of brain cancer. J Clin Oncol. 2008;26(17):2916–24.

    PubMed  Article  Google Scholar 

  72. 72.

    Otte J, Dizdar L, Behrens B, Goering W, Knoefel WT, Wruck W, et al. FGF Signalling in the Self-Renewal of Colon Cancer Organoids. Sci Rep. 2019;9(1):17365.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  73. 73.

    Fulda S. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets. 2009;9(6):729–37.

    PubMed  Article  CAS  Google Scholar 

  74. 74.

    Mabuchi S, Kuroda H, Takahashi R, Sasano T. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol Oncol. 2015;137(1):173–9.

    PubMed  Article  CAS  Google Scholar 

  75. 75.

    Shahcheraghi SH, Tchokonte-Nana V, Lotfi M, Lotfi M, Ghorbani A, Sadeghnia HR. Wnt/beta-catenin and PI3K/Akt/mtor Signaling Pathways in Glioblastoma: Two main targets for drug design: A Review. Curr Pharm Des. 2020. Published online ahead of print, https://doi.org/10.2174/1381612826666200131100630.

  76. 76.

    Jurkowska RZ, Jurkowski TP, Jeltsch A. Structure and function of mammalian DNA methyltransferases. Chembiochem Eur J Chem Biol. 2011;12(2):206–22.

    Article  CAS  Google Scholar 

  77. 77.

    Koh KP, Yabuuchi A, Rao S, Huang Y, Cunniff K, Nardone J, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell. 2011;8(2):200–13.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  78. 78.

    Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006;441(7091):349–53.

    PubMed  Article  CAS  Google Scholar 

  79. 79.

    Taneja G, Maity S, Jiang W, Moorthy B, Coarfa C, Ghose R. Transcriptomic profiling identifies novel mechanisms of transcriptional regulation of the cytochrome P450 (Cyp)3a11 gene. Sci Rep. 2019;9(1):6663.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  80. 80.

    Siddique HR, Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells. 2012;30(3):372–8.

    PubMed  Article  CAS  Google Scholar 

  81. 81.

    Morita R, Hirohashi Y, Suzuki H, Takahashi A, Tamura Y, Kanaseki T, et al. DNA methyltransferase 1 is essential for initiation of the colon cancers. Exp Mol Pathol. 2013;94(2):322–9.

    PubMed  Article  CAS  Google Scholar 

  82. 82.

    Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell. 2013;154(2):311–24.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  83. 83.

    van Vlerken LE, Kiefer CM, Morehouse C, Li Y, Groves C, Wilson SD, et al. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Stem Cells Transl Med. 2013;2(1):43–52.

    PubMed  Article  CAS  Google Scholar 

  84. 84.

    Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res. 2009;69(24):9211–8.

    PubMed  Article  CAS  Google Scholar 

  85. 85.

    Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM, et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A. 2009;106(13):5324–9.

    PubMed  PubMed Central  Article  Google Scholar 

  86. 86.

    Jin J, Lv X, Chen L, Zhang W, Li J, Wang Q, et al. Bmi-1 plays a critical role in protection from renal tubulointerstitial injury by maintaining redox balance. Aging Cell. 2014;13(5):797–809.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  87. 87.

    Nor C, Zhang Z, Warner KA, Bernardi L, Visioli F, Helman JI, et al. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer. Neoplasia. 2014;16(2):137–46.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  88. 88.

    Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, Davis T, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014;20(1):29–36.

    PubMed  Article  CAS  Google Scholar 

  89. 89.

    Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Haematol. 2008;142(2):149–65.

    PubMed  Article  CAS  Google Scholar 

  90. 90.

    Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell. 2010;39(5):761–72.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  91. 91.

    Heddleston JM, Wu Q, Rivera M, Minhas S, Lathia JD, Sloan AE, et al. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ. 2012;19(3):428–39.

    PubMed  Article  CAS  Google Scholar 

  92. 92.

    Choi DS, Blanco E, Kim YS, Rodriguez AA, Zhao H, Huang TH, et al. Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1. Stem Cells. 2014;32(9):2309–23.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  93. 93.

    Ferrone CK, Blydt-Hansen M, Rauh MJ. Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease. Int J Mol Sci. 2020;21(2):626.

  94. 94.

    Yu X, Jiang X, Li H, Guo L, Jiang W, Lu SH. miR-203 inhibits the proliferation and self-renewal of esophageal cancer stem-like cells by suppressing stem renewal factor Bmi-1. Stem Cells Dev. 2014;23(6):576–85.

    PubMed  Article  CAS  Google Scholar 

  95. 95.

    Yu D, Liu Y, Yang J, Jin C, Zhao X, Cheng J, et al. Clinical implications of BMI-1 in cancer stem cells of laryngeal carcinoma. Cell Biochem Biophys. 2015;71(1):261–9.

    PubMed  Article  CAS  Google Scholar 

  96. 96.

    Chang B, Li S, He Q, Liu Z, Zhao L, Zhao T, et al. Deregulation of Bmi-1 is associated with enhanced migration, invasion and poor prognosis in salivary adenoid cystic carcinoma. Biochim Biophys Acta. 2014;1840(12):3285–91.

    PubMed  Article  CAS  Google Scholar 

  97. 97.

    Benoit YD, Witherspoon MS, Laursen KB, Guezguez A, Beausejour M, Beaulieu JF, et al. Pharmacological inhibition of polycomb repressive complex-2 activity induces apoptosis in human colon cancer stem cells. Exp Cell Res. 2013;319(10):1463–70.

    PubMed  Article  CAS  Google Scholar 

  98. 98.

    Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science. 2008;320(5872):97–100.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  99. 99.

    Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. Rna. 2008;14(8):1539–49.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  100. 100.

    Yu L, Xu Y, Qu H, Yu Y, Li W, Zhao Y, et al. Decrease of MiR-31 induced by TNF-alpha inhibitor activates SATB2/RUNX2 pathway and promotes osteogenic differentiation in ethanol-induced osteonecrosis. J Cell Physiol. 2019;234(4):4314–26.

    PubMed  Article  CAS  Google Scholar 

  101. 101.

    Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137(4):647–58.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  102. 102.

    Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11(12):1487–95.

    PubMed  Article  CAS  Google Scholar 

  103. 103.

    Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, et al. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell. 2013;25(1):69–80.

    PubMed  Article  CAS  Google Scholar 

  104. 104.

    Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131(6):1109–23.

    PubMed  Article  CAS  Google Scholar 

  105. 105.

    Garg M. Epithelial, mesenchymal and hybrid epithelial/mesenchymal phenotypes and their clinical relevance in cancer metastasis. Expert Rev Mol Med. 2017;19:e3.

    PubMed  Article  CAS  Google Scholar 

  106. 106.

    Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 2009;69(19):7569–76.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  107. 107.

    Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4(8):e6816.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  108. 108.

    Bu P, Chen KY, Chen JH, Wang L, Walters J, Shin YJ, et al. A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell. 2013;12(5):602–15.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  109. 109.

    Yang YP, Chien Y, Chiou GY, Cherng JY, Wang ML, Lo WL, et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using microRNA145 with cationic polyurethane-short branch PEI. Biomaterials. 2012;33(5):1462–76.

    PubMed  Article  CAS  Google Scholar 

  110. 110.

    Geng YJ, Xie SL, Li Q, Ma J, Wang GY. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res. 2011;39(6):2119–28.

    PubMed  Article  CAS  Google Scholar 

  111. 111.

    Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17(2):211–5.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  112. 112.

    Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D, et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer. 2008;8:266.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  113. 113.

    Alison MR, Poulsom R, Forbes S, Wright NA. An introduction to stem cells. J Pathol. 2002;197(4):419–23.

    PubMed  Article  Google Scholar 

  114. 114.

    Gerson SL, Reese J, Kenyon J. DNA repair in stem cell maintenance and conversion to cancer stem cells. Ernst Schering Foundation Symp Proc. 2006;5:231–44.

    Google Scholar 

  115. 115.

    Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54(5):716–27.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  116. 116.

    Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756–60.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  117. 117.

    Olcina M, Lecane PS, Hammond EM. Targeting hypoxic cells through the DNA damage response. Clin Cancer Res. 2010;16(23):5624–9.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  118. 118.

    Jones DL, Wagers AJ. No place like home: anatomy and function of the stem cell niche. Nature reviews. Mol Cell Biol. 2008;9(1):11–21.

    CAS  Google Scholar 

  119. 119.

    Borovski T, De Sousa EMF, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be. Cancer Res. 2011;71(3):634–9.

    PubMed  Article  CAS  Google Scholar 

  120. 120.

    Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell. 2015;16(3):225–38.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  121. 121.

    Tetteh PW, Farin HF, Clevers H. Plasticity within stem cell hierarchies in mammalian epithelia. Trends Cell Biol. 2015;25(2):100–8.

    PubMed  Article  CAS  Google Scholar 

  122. 122.

    Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A. 2011;108(19):7950–5.

    PubMed  PubMed Central  Article  Google Scholar 

  123. 123.

    Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, Chambers I, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 1998;95(3):379–91.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  124. 124.

    Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000;24(4):372–6.

    PubMed  Article  CAS  Google Scholar 

  125. 125.

    Shimozaki K, Nakashima K, Niwa H, Taga T. Involvement of Oct3/4 in the enhancement of neuronal differentiation of ES cells in neurogenesis-inducing cultures. Development. 2003;130(11):2505–12.

    PubMed  Article  CAS  Google Scholar 

  126. 126.

    Xu K, Zhu Z, Zeng F. Expression and significance of Oct4 in bladder cancer. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. 2007;27(6):675–7.

    Google Scholar 

  127. 127.

    Hatefi N, Nouraee N, Parvin M, Ziaee SA, Mowla SJ. Evaluating the expression of oct4 as a prognostic tumor marker in bladder cancer. Iran J Basic Med Sci. 2012;15(6):1154–61.

    PubMed  PubMed Central  CAS  Google Scholar 

  128. 128.

    de Resende MF, Chinen LT, Vieira S, Jampietro J, da Fonseca FP, Vassallo J, et al. Prognostication of OCT4 isoform expression in prostate cancer. Tumour Biol. 2013;34(5):2665–73.

    PubMed  Article  CAS  Google Scholar 

  129. 129.

    Rodini CO, Suzuki DE, Saba-Silva N, Cappellano A, de Souza JE, Cavalheiro S, et al. Expression analysis of stem cell-related genes reveal OCT4 as a predictor of poor clinical outcome in medulloblastoma. J Neurooncol. 2012;106(1):71–9.

    PubMed  Article  CAS  Google Scholar 

  130. 130.

    Li C, Yan Y, Ji W, Bao L, Qian H, Chen L, et al. OCT4 positively regulates Survivin expression to promote cancer cell proliferation and leads to poor prognosis in esophageal squamous cell carcinoma. PLoS One. 2012;7(11):e49693.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  131. 131.

    Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 2003;17(1):126–40.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  132. 132.

    Masui S, Nakatake Y, Toyooka Y, Shimosato D, Yagi R, Takahashi K, et al. Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol. 2007;9(6):625–35.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  133. 133.

    Boer B, Kopp J, Mallanna S, Desler M, Chakravarthy H, Wilder PJ, et al. Elevating the levels of Sox2 in embryonal carcinoma cells and embryonic stem cells inhibits the expression of Sox2:Oct-3/4 target genes. Nucleic Acids Res. 2007;35(6):1773–86.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  134. 134.

    Kopp JL, Ormsbee BD, Desler M, Rizzino A. Small increases in the level of Sox2 trigger the differentiation of mouse embryonic stem cells. Stem Cells. 2008;26(4):903–11.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  135. 135.

    Ying J, Shi C, Li CS, Hu LP, Zhang WD. Expression and significance of SOX2 in non-small cell lung carcinoma. Oncol Lett. 2016;12(5):3195–8.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  136. 136.

    Wang Q, He W, Lu C, Wang Z, Wang J, Giercksky KE, et al. Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res. 2009;29(4):1233–41.

    PubMed  CAS  Google Scholar 

  137. 137.

    Forghanifard MM, Ardalan Khales S, Javdani-Mallak A, Rad A, Farshchian M, Abbaszadegan MR. Stemness state regulators SALL4 and SOX2 are involved in progression and invasiveness of esophageal squamous cell carcinoma. Med Oncol. 2014;31(4):922.

    PubMed  Article  CAS  Google Scholar 

  138. 138.

    Li XL, Eishi Y, Bai YQ, Sakai H, Akiyama Y, Tani M, et al. Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol. 2004;24(2):257–63.

    PubMed  CAS  Google Scholar 

  139. 139.

    Zhang X, Yu H, Yang Y, Zhu R, Bai J, Peng Z, et al. SOX2 in gastric carcinoma, but not Hath1, is related to patients' clinicopathological features and prognosis. J Gastrointestinal Surg. 2010;14(8):1220–6.

    Article  Google Scholar 

  140. 140.

    Matsuoka J, Yashiro M, Sakurai K, Kubo N, Tanaka H, Muguruma K, et al. Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma. J Surg Res. 2012;174(1):130–5.

    PubMed  Article  CAS  Google Scholar 

  141. 141.

    Li X, Wang J, Xu Z, Ahmad A, Li E, Wang Y, et al. Expression of Sox2 and Oct4 and their clinical significance in human non-small-cell lung cancer. Int J Mol Sci. 2012;13(6):7663–75.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  142. 142.

    Chen Y, Huang Y, Huang Y, Chen J, Wang S, Zhou J. The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis. PLoS One. 2013;8(8):e71140.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  143. 143.

    Inoue Y, Matsuura S, Kurabe N, Kahyo T, Mori H, Kawase A, et al. Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2–1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification. J Thoracic Oncol. 2015;10(11):1590–600.

    Article  CAS  Google Scholar 

  144. 144.

    Leis O, Eguiara A, Lopez-Arribillaga E, Alberdi MJ, Hernandez-Garcia S, Elorriaga K, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2012;31(11):1354–65.

    PubMed  Article  CAS  Google Scholar 

  145. 145.

    Gillis AJ, Stoop H, Biermann K, van Gurp RJ, Swartzman E, Cribbes S, et al. Expression and interdependencies of pluripotency factors LIN28, OCT3/4, NANOG and SOX2 in human testicular germ cells and tumours of the testis. Int J Androl. 2011;34(4 Pt 2):e160–74.

    PubMed  Article  CAS  Google Scholar 

  146. 146.

    Pham DL, Scheble V, Bareiss P, Fischer A, Beschorner C, Adam A, et al. SOX2 expression and prognostic significance in ovarian carcinoma. Int J Gynecol Pathol. 2013;32(4):358–67.

    PubMed  Article  CAS  Google Scholar 

  147. 147.

    Ivanova N, Dobrin R, Lu R, Kotenko I, Levorse J, DeCoste C, et al. Dissecting self-renewal in stem cells with RNA interference. Nature. 2006;442(7102):533–8.

    PubMed  Article  CAS  Google Scholar 

  148. 148.

    Ghaleb AM, Nandan MO, Chanchevalap S, Dalton WB, Hisamuddin IM, Yang VW. Kruppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation. Cell Res. 2005;15(2):92–6.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  149. 149.

    Bourillot PY, Savatier P. Kruppel-like transcription factors and control of pluripotency. BMC Biol. 2010;8:125.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  150. 150.

    Leng Z, Tao K, Xia Q, Tan J, Yue Z, Chen J, et al. Kruppel-like factor 4 acts as an oncogene in colon cancer stem cell-enriched spheroid cells. PLoS One. 2013;8(2):e56082.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  151. 151.

    Nakatake Y, Fukui N, Iwamatsu Y, Masui S, Takahashi K, Yagi R, et al. Klf4 cooperates with Oct3/4 and Sox2 to activate the Lefty1 core promoter in embryonic stem cells. Mol Cell Biol. 2006;26(20):7772–82.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  152. 152.

    Jiang J, Chan YS, Loh YH, Cai J, Tong GQ, Lim CA, et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat Cell Biol. 2008;10(3):353–60.

    PubMed  Article  CAS  Google Scholar 

  153. 153.

    Patel NV, Ghaleb AM, Nandan MO, Yang VW. Expression of the tumor suppressor Kruppel-like factor 4 as a prognostic predictor for colon cancer. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2631–8.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  154. 154.

    Tai SK, Yang MH, Chang SY, Chang YC, Li WY, Tsai TL, et al. Persistent Kruppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma. Cancer Sci. 2011;102(4):895–902.

    PubMed  Article  CAS  Google Scholar 

  155. 155.

    Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, et al. Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer. Clin Cancer Res. 2004;10(8):2709–19.

    PubMed  Article  CAS  Google Scholar 

  156. 156.

    Liu Z, Yang H, Luo W, Jiang Q, Mai C, Chen Y, et al. Loss of cytoplasmic KLF4 expression is correlated with the progression and poor prognosis of nasopharyngeal carcinoma. Histopathology. 2013;63(3):362–70.

    PubMed  Article  Google Scholar 

  157. 157.

    Chen CJ, Hsu LS, Lin SH, Chen MK, Wang HK, Hsu JD, et al. Loss of nuclear expression of Kruppel-like factor 4 is associated with poor prognosis in patients with oral cancer. Hum Pathol. 2012;43(7):1119–25.

    PubMed  Article  CAS  Google Scholar 

  158. 158.

    Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M, Takahashi K, et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003;113(5):631–42.

    PubMed  Article  CAS  Google Scholar 

  159. 159.

    Chambers I, Colby D, Robertson M, Nichols J, Lee S, Tweedie S, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003;113(5):643–55.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  160. 160.

    Silva J, Nichols J, Theunissen TW, Guo G, van Oosten AL, Barrandon O, et al. Nanog is the gateway to the pluripotent ground state. Cell. 2009;138(4):722–37.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  161. 161.

    Kuroda T, Tada M, Kubota H, Kimura H, Hatano SY, Suemori H, et al. Octamer and Sox elements are required for transcriptional cis regulation of Nanog gene expression. Mol Cell Biol. 2005;25(6):2475–85.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  162. 162.

    Chen X, Xu H, Yuan P, Fang F, Huss M, Vega VB, et al. Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell. 2008;133(6):1106–17.

    PubMed  Article  CAS  Google Scholar 

  163. 163.

    Lerchl A. Letter on 'The effect of pulsed 900-MHz GSM mobile phone radiation on the acrosome reaction, head morphometry and zona binding of human spermatozoa' by Falzone et al. (Int J Androl 34: 20–26, 2011). Int J Androl. 2012;35(1):103 author reply 04.

    PubMed  Article  CAS  Google Scholar 

  164. 164.

    Meng HM, Zheng P, Wang XY, Liu C, Sui HM, Wu SJ, et al. Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer. Cancer Biol Ther. 2010;9(4):295–302.

    PubMed  Article  CAS  Google Scholar 

  165. 165.

    Chen H, Laba JM, Boldt RG, Goodman CD, Palma DA, Senan S, et al. Stereotactic Ablative Radiation Therapy Versus Surgery in Early Lung Cancer: A Meta-analysis of Propensity Score Studies. Int J Radiat Oncol Biol Phys. 2018;101(1):186–94.

    PubMed  Article  Google Scholar 

  166. 166.

    Li XQ, Yang XL, Zhang G, Wu SP, Deng XB, Xiao SJ, et al. Nuclear beta-catenin accumulation is associated with increased expression of Nanog protein and predicts poor prognosis of non-small cell lung cancer. J Transl Med. 2013;11:114.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  167. 167.

    Lee M, Nam EJ, Kim SW, Kim S, Kim JH, Kim YT. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma. Int J Gynecol Cancer. 2012;22(9):1489–96.

    PubMed  Article  Google Scholar 

  168. 168.

    Sun C, Sun L, Jiang K, Gao DM, Kang XN, Wang C, et al. NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. Int J Biochem Cell Biol. 2013;45(6):1099–108.

    PubMed  Article  CAS  Google Scholar 

  169. 169.

    Cole MD, Henriksson M. 25 years of the c-Myc oncogene. Semin Cancer Biol. 2006;16(4):241.

    PubMed  Article  Google Scholar 

  170. 170.

    Laurenti E, Wilson A, Trumpp A. Myc's other life: stem cells and beyond. Curr Opin Cell Biol. 2009;21(6):844–54.

    PubMed  Article  CAS  Google Scholar 

  171. 171.

    Meyer N, Kim SS, Penn LZ. The Oscar-worthy role of Myc in apoptosis. Semin Cancer Biol. 2006;16(4):275–87.

    PubMed  Article  CAS  Google Scholar 

  172. 172.

    Cartwright P, McLean C, Sheppard A, Rivett D, Jones K, Dalton S. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development. 2005;132(5):885–96.

    PubMed  Article  CAS  Google Scholar 

  173. 173.

    Chappell J, Sun Y, Singh A, Dalton S. MYC/MAX control ERK signaling and pluripotency by regulation of dual-specificity phosphatases 2 and 7. Genes Dev. 2013;27(7):725–33.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  174. 174.

    Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 2010;143(2):313–24.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  175. 175.

    Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22–35.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  176. 176.

    Wang Y, Wu MC, Sham JS, Zhang W, Wu WQ, Guan XY. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer. 2002;95(11):2346–52.

    PubMed  Article  CAS  Google Scholar 

  177. 177.

    Riou G, Barrois M, Le MG, George M, Le Doussal V, Haie C. C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix. Lancet. 1987;1(8536):761–3.

    PubMed  Article  CAS  Google Scholar 

  178. 178.

    Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii27–32.

    PubMed  Article  Google Scholar 

  179. 179.

    Poli V, Fagnocchi L, Fasciani A, Cherubini A, Mazzoleni S, Ferrillo S, et al. MYC-driven epigenetic reprogramming favors the onset of tumorigenesis by inducing a stem cell-like state. Nat Commun. 2018;9(1):1024.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  180. 180.

    Krizhanovsky V, Lowe SW. Stem cells: The promises and perils of p53. Nature. 2009;460(7259):1085–6.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  181. 181.

    Spike BT, Wahl GM. p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome. Genes Cancer. 2011;2(4):404–19.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  182. 182.

    Jiang H, Xu Z, Zhong P, Ren Y, Liang G, Schilling HA, et al. Cell cycle and p53 gate the direct conversion of human fibroblasts to dopaminergic neurons. Nat Commun. 2015;6:10100.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  183. 183.

    Aronheim A, Zandi E, Hennemann H, Elledge SJ, Karin M. Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions. Mol Cell Biol. 1997;17(6):3094–102.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  184. 184.

    Jin C, Li H, Murata T, Sun K, Horikoshi M, Chiu R, et al. JDP2, a repressor of AP-1, recruits a histone deacetylase 3 complex to inhibit the retinoic acid-induced differentiation of F9 cells. Mol Cell Biol. 2002;22(13):4815–26.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  185. 185.

    Tsai MH, Wuputra K, Lin YC, Lin CS, Yokoyama KK. Multiple functions of the histone chaperone Jun dimerization protein 2. Gene. 2016;590(2):193–200.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  186. 186.

    Pan J, Nakade K, Huang YC, Zhu ZW, Masuzaki S, Hasegawa H, et al. Suppression of cell-cycle progression by Jun dimerization protein-2 (JDP2) involves downregulation of cyclin-A2. Oncogene. 2011;30:3648.

    PubMed Central  Article  CAS  Google Scholar 

  187. 187.

    Weidenfeld-Baranboim K, Bitton-Worms K, Aronheim A. TRE-dependent transcription activation by JDP2-CHOP10 association. Nucleic Acids Res. 2008;36(11):3608–19.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  188. 188.

    Saito S, Lin YC, Tsai MH, Lin CS, Murayama Y, Sato R, et al. Emerging roles of hypoxia-inducible factors and reactive oxygen species in cancer and pluripotent stem cells. Kaohsiung J Med Sci. 2015;31(6):279–86.

    PubMed  Article  Google Scholar 

  189. 189.

    Tanigawa S, Lee CH, Lin CS, Ku CC, Hasegawa H, Qin S, et al. Jun dimerization protein 2 is a critical component of the Nrf2/MafK complex regulating the response to ROS homeostasis. Cell Death Dis. 2013;4:e921.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  190. 190.

    Esteban MA, Wang T, Qin B, Yang J, Qin D, Cai J, et al. Vitamin C enhances the generation of mouse and human induced pluripotent stem cells. Cell Stem Cell. 2010;6(1):71–9.

    PubMed  Article  CAS  Google Scholar 

  191. 191.

    Kielman MF, Rindapaa M, Gaspar C, van Poppel N, Breukel C, van Leeuwen S, et al. Apc modulates embryonic stem-cell differentiation by controlling the dosage of beta-catenin signaling. Nat Genet. 2002;32(4):594–605.

    PubMed  Article  CAS  Google Scholar 

  192. 192.

    Marson A, Foreman R, Chevalier B, Bilodeau S, Kahn M, Young RA, et al. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell Stem Cell. 2008;3(2):132–5.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  193. 193.

    Ogawa K, Nishinakamura R, Iwamatsu Y, Shimosato D, Niwa H. Synergistic action of Wnt and LIF in maintaining pluripotency of mouse ES cells. Biochem Biophys Res Commun. 2006;343(1):159–66.

    PubMed  Article  CAS  Google Scholar 

  194. 194.

    Takao Y, Yokota T, Koide H. Beta-catenin up-regulates Nanog expression through interaction with Oct-3/4 in embryonic stem cells. Biochem Biophys Res Commun. 2007;353(3):699–705.

    PubMed  Article  CAS  Google Scholar 

  195. 195.

    Wu DC, Wang SSW, Liu CJ, Wuputra K, Kato K, Lee YL, et al. Reprogramming Antagonizes the Oncogenicity of HOXA13-Long Noncoding RNA HOTTIP Axis in Gastric Cancer Cells. Stem Cells. 2017;35(10):2115–28.

    PubMed  Article  CAS  Google Scholar 

  196. 196.

    Weigmann A, Corbeil D, Hellwig A, Huttner WB. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci U S A. 1997;94(23):12425–30.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  197. 197.

    Glumac PM, LeBeau AM. The role of CD133 in cancer: a concise review. Clin Transl Med. 2018;7(1):18.

    PubMed  PubMed Central  Article  Google Scholar 

  198. 198.

    Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  199. 199.

    Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG. Colorectal cancer stem cells. Stem Cells. 2012;30(3):363–71.

    PubMed  Article  CAS  Google Scholar 

  200. 200.

    O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445(7123):106–10.

    PubMed  Article  CAS  Google Scholar 

  201. 201.

    Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15(3):504–14.

    PubMed  Article  CAS  Google Scholar 

  202. 202.

    Lin SH, Liu T, Ming X, Tang Z, Fu L, Schmitt-Kopplin P, et al. Regulatory role of hexosamine biosynthetic pathway on hepatic cancer stem cell marker CD133 under low glucose conditions. Sci Rep. 2016;6:21184.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  203. 203.

    Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946–51.

    PubMed  Article  CAS  Google Scholar 

  204. 204.

    Chen H, Luo Z, Dong L, Tan Y, Yang J, Feng G, et al. CD133/prominin-1-mediated autophagy and glucose uptake beneficial for hepatoma cell survival. PLoS One. 2013;8(2):e56878.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  205. 205.

    Du L, Wang H, He L, Zhang J, Ni B, Wang X, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14(21):6751–60.

    PubMed  Article  CAS  Google Scholar 

  206. 206.

    Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118(6):2111–20.

    PubMed  PubMed Central  CAS  Google Scholar 

  207. 207.

    Misra S, Hascall VC, Berger FG, Markwald RR, Ghatak S. Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer. Connect Tissue Res. 2008;49(3):219–24.

    PubMed  Article  CAS  Google Scholar 

  208. 208.

    Ghatak S, Misra S, Toole BP. Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem. 2005;280(10):8875–83.

    PubMed  Article  CAS  Google Scholar 

  209. 209.

    Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer. Front Immunol. 2015;6:201.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  210. 210.

    Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  211. 211.

    Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17(10):1253–70.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  212. 212.

    Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006;25(12):1696–708.

    PubMed  Article  CAS  Google Scholar 

  213. 213.

    Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44+ CD24(−) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer. 2008;98(4):756–65.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  214. 214.

    Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A. 2007;104(24):10158–63.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  215. 215.

    Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14(3):342–56.

    PubMed  Article  CAS  Google Scholar 

  216. 216.

    Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030–7.

    PubMed  Article  CAS  Google Scholar 

  217. 217.

    Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104(3):973–8.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  218. 218.

    Hang D, Dong HC, Ning T, Dong B, Hou DL, Xu WG. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma. Dis Esophagus. 2012;25(7):638–44.

    PubMed  Article  CAS  Google Scholar 

  219. 219.

    Ding XW, Wu JH, Jiang CP. ABCG2: a potential marker of stem cells and novel target in stem cell and cancer therapy. Life Sci. 2010;86(17–18):631–7.

    PubMed  Article  CAS  Google Scholar 

  220. 220.

    Zhang G, Wang Z, Luo W, Jiao H, Wu J, Jiang C. Expression of Potential Cancer Stem Cell Marker ABCG2 is Associated with Malignant Behaviors of Hepatocellular Carcinoma. Gastroenterol Res Pract. 2013;2013:782581.

    PubMed  PubMed Central  Google Scholar 

  221. 221.

    Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest. 2010;120(9):3326–39.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  222. 222.

    Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K, Kohno N, et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology. 2002;122(2):376–86.

    PubMed  Article  CAS  Google Scholar 

  223. 223.

    Schreiber CL, Smith BD. Molecular Imaging of Aminopeptidase N in Cancer and Angiogenesis. Contrast Media Mol Imaging. 2018;2018:5315172.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  224. 224.

    Al-Kharusi MR, Smartt HJ, Greenhough A, Collard TJ, Emery ED, Williams AC, et al. LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: implications for targeting adenoma stem cells with NSAIDs. Carcinogenesis. 2013;34(5):1150–7.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  225. 225.

    Lebensohn AM, Rohatgi R. R-spondins can potentiate WNT signaling without LGRs. eLife. 2018;7:e33126.

  226. 226.

    Zhou X, Geng L, Wang D, Yi H, Talmon G, Wang J. R-Spondin1/LGR5 Activates TGFbeta Signaling and Suppresses Colon Cancer Metastasis. Cancer Res. 2017;77(23):6589–602.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  227. 227.

    Walker F, Zhang HH, Odorizzi A, Burgess AW. LGR5 is a negative regulator of tumourigenicity, antagonizes Wnt signalling and regulates cell adhesion in colorectal cancer cell lines. PLoS One. 2011;6(7):e22733.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  228. 228.

    Haegebarth A, Clevers H. Wnt signaling, lgr5, and stem cells in the intestine and skin. Am J Pathol. 2009;174(3):715–21.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  229. 229.

    Morgan RG, Mortensson E, Williams AC. Targeting LGR5 in Colorectal Cancer: therapeutic gold or too plastic? Br J Cancer. 2018;118(11):1410–8.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  230. 230.

    Anderson R, Schaible K, Heasman J, Wylie C. Expression of the homophilic adhesion molecule, Ep-CAM, in the mammalian germ line. J Reprod Fertil. 1999;116(2):379–84.

    PubMed  Article  CAS  Google Scholar 

  231. 231.

    Huang L, Yang Y, Yang F, Liu S, Zhu Z, Lei Z, et al. Functions of EpCAM in physiological processes and diseases (Review). Int J Mol Med. 2018;42(4):1771–85.

    PubMed  PubMed Central  CAS  Google Scholar 

  232. 232.

    Cochrane CR, Szczepny A, Watkins DN, Cain JE. Hedgehog Signaling in the Maintenance of Cancer Stem Cells. Cancers. 2015;7(3):1554–85.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  233. 233.

    Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008;22(18):2454–72.

    PubMed  Article  CAS  Google Scholar 

  234. 234.

    Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12(8):445–64.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  235. 235.

    Yu X, Zou J, Ye Z, Hammond H, Chen G, Tokunaga A, et al. Notch signaling activation in human embryonic stem cells is required for embryonic, but not trophoblastic, lineage commitment. Cell Stem Cell. 2008;2(5):461–71.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  236. 236.

    Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, et al. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369(1):20–7.

    Article  CAS  Google Scholar 

  237. 237.

    Stine RR, Matunis EL. JAK-STAT signaling in stem cells. Adv Exp Med Biol. 2013;786:247–67.

    PubMed  Article  CAS  Google Scholar 

  238. 238.

    Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16(8):797–803.

    PubMed  Article  CAS  Google Scholar 

  239. 239.

    Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res. 2012;18(21):5856–64.

    PubMed  Article  CAS  Google Scholar 

  240. 240.

    Dos Santos C, Recher C, Demur C, Payrastre B. The PI3K/Akt/mTOR pathway: a new therapeutic target in the treatment of acute myeloid leukemia. Bull Cancer. 2006;93(5):445–7.

    PubMed  Google Scholar 

  241. 241.

    Valkenburg KC, Graveel CR, Zylstra-Diegel CR, Zhong Z, Williams BO. Wnt/beta-catenin Signaling in Normal and Cancer Stem Cells. Cancers. 2011;3(2):2050–79.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  242. 242.

    Ashihara E, Takada T, Maekawa T. Targeting the canonical Wnt/beta-catenin pathway in hematological malignancies. Cancer Sci. 2015;106(6):665–71.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  243. 243.

    Gedaly R, Galuppo R, Daily MF, Shah M, Maynard E, Chen C, et al. Targeting the Wnt/beta-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535. PLoS One. 2014;9(6):e99272.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  244. 244.

    Yao H, Ashihara E, Maekawa T. Targeting the Wnt/beta-catenin signaling pathway in human cancers. Expert Opin Ther Targets. 2011;15(7):873–87.

    PubMed  Article  CAS  Google Scholar 

  245. 245.

    De S, Ganesan S. Looking beyond drivers and passengers in cancer genome sequencing data. Ann Oncol. 2017;28(5):938–45.

    PubMed  Article  CAS  Google Scholar 

  246. 246.

    Pon JR, Marra MA. Driver and passenger mutations in cancer. Annu Rev Pathol. 2015;10:25–50.

    PubMed  Article  CAS  Google Scholar 

  247. 247.

    Gonzalez-Perez A, Mustonen V, Reva B, Ritchie GR, Creixell P, Karchin R, et al. Computational approaches to identify functional genetic variants in cancer genomes. Nat Methods. 2013;10(8):723–9.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  248. 248.

    Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11(10):685–96.

    PubMed  Article  CAS  Google Scholar 

  249. 249.

    Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013;14(10):703–18.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  250. 250.

    Kato S, Lippman SM, Flaherty KT, Kurzrock R. The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst. 2016;108(8):djw036.

  251. 251.

    Treutlein B, Brownfield DG, Wu AR, Neff NF, Mantalas GL, Espinoza FH, et al. Reconstructing lineage hierarchies of the distal lung epithelium using single-cell RNA-seq. Nature. 2014;509(7500):371–5.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  252. 252.

    Halpern KB, Shenhav R, Matcovitch-Natan O, Toth B, Lemze D, Golan M, et al. Single-cell spatial reconstruction reveals global division of labour in the mammalian liver. Nature. 2017;542(7641):352–6.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  253. 253.

    Wang YJ, Schug J, Won KJ, Liu C, Naji A, Avrahami D, et al. Single-Cell Transcriptomics of the Human Endocrine Pancreas. Diabetes. 2016;65(10):3028–38.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  254. 254.

    Muraro MJ, Dharmadhikari G, Grun D, Groen N, Dielen T, Jansen E, et al. A Single-Cell Transcriptome Atlas of the Human Pancreas. Cell Systems. 2016;3(4):385–94 e3.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  255. 255.

    Barriga FM, Montagni E, Mana M, Mendez-Lago M, Hernando-Momblona X, Sevillano M, et al. Mex3a Marks a Slowly Dividing Subpopulation of Lgr5+ Intestinal Stem Cells. Cell Stem Cell. 2017;20(6):801–16 e7.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  256. 256.

    Johnson E, Dickerson KL, Connolly ID, Hayden GM. Single-Cell RNA-Sequencing in Glioma. Curr Oncol Rep. 2018;20(5):42.

    PubMed  Article  CAS  Google Scholar 

  257. 257.

    Kilpinen H, Goncalves A, Leha A, Afzal V, Alasoo K, Ashford S, et al. Common genetic variation drives molecular heterogeneity in human iPSCs. Nature. 2017;546(7658):370–5.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  258. 258.

    Voog J, Jones DL. Stem cells and the niche: a dynamic duo. Cell Stem Cell. 2010;6(2):103–15.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  259. 259.

    Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21(3):309–22.

    PubMed  Article  CAS  Google Scholar 

  260. 260.

    Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest. 2011;121(10):3804–9.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  261. 261.

    Shue YT, Lim JS, Sage J. Tumor heterogeneity in small cell lung cancer defined and investigated in pre-clinical mouse models. Transl Lung Cancer Res. 2018;7(1):21–31.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  262. 262.

    Fessler E, Dijkgraaf FE, De Sousa EMF, Medema JP. Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? Cancer Lett. 2013;341(1):97–104.

    PubMed  Article  CAS  Google Scholar 

  263. 263.

    Kumano K, Arai S, Hosoi M, Taoka K, Takayama N, Otsu M, et al. Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. Blood. 2012;119(26):6234–42.

    PubMed  Article  CAS  Google Scholar 

  264. 264.

    Wang B, Miyagoe-Suzuki Y, Yada E, Ito N, Nishiyama T, Nakamura M, et al. Reprogramming efficiency and quality of induced Pluripotent Stem Cells (iPSCs) generated from muscle-derived fibroblasts of mdx mice at different ages. PLoS Currents. 2011;3:RRN1274.

    PubMed  PubMed Central  Article  Google Scholar 

  265. 265.

    Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011;11(4):268–77.

    PubMed  Article  CAS  Google Scholar 

  266. 266.

    Goldring CE, Duffy PA, Benvenisty N, Andrews PW, Ben-David U, Eakins R, et al. Assessing the safety of stem cell therapeutics. Cell Stem Cell. 2011;8(6):618–28.

    PubMed  Article  CAS  Google Scholar 

  267. 267.

    Daniel FI, Cherubini K, Yurgel LS, de Figueiredo MA, Salum FG. The role of epigenetic transcription repression and DNA methyltransferases in cancer. Cancer. 2011;117(4):677–87.

    PubMed  Article  CAS  Google Scholar 

  268. 268.

    McDonald OG, Li X, Saunders T, Tryggvadottir R, Mentch SJ, Warmoes MO, et al. Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat Genet. 2017;49(3):367–76.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  269. 269.

    Roe JS, Hwang CI, Somerville TDD, Milazzo JP, Lee EJ, Da Silva B, et al. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis. Cell. 2017;170(5):875–88 e20.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  270. 270.

    Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012;81(4):303–11.

    PubMed  Article  CAS  Google Scholar 

  271. 271.

    Pattani KM, Soudry E, Glazer CA, Ochs MF, Wang H, Schussel J, et al. MAGEB2 is activated by promoter demethylation in head and neck squamous cell carcinoma. PLoS One. 2012;7(9):e45534.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  272. 272.

    Skvortsova K, Iovino N, Bogdanovic O. Functions and mechanisms of epigenetic inheritance in animals. Nature reviews. Mol Cell Biol. 2018;19(12):774–90.

    CAS  Google Scholar 

  273. 273.

    Sabari BR, Dall'Agnese A, Boija A, Klein IA, Coffey EL, Shrinivas K, et al. Coactivator condensation at super-enhancers links phase separation and gene control. Science. 2018;361(6400):eaar3958.

  274. 274.

    Guo YE, Manteiga JC, Henninger JE, Sabari BR, Dall'Agnese A, Hannett NM, et al. Pol II phosphorylation regulates a switch between transcriptional and splicing condensates. Nature. 2019;572(7770):543–8.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  275. 275.

    Li S, Zheng EB, Zhao L, Liu S. Nonreciprocal and Conditional Cooperativity Directs the Pioneer Activity of Pluripotency Transcription Factors. Cell Rep. 2019;28(10):2689–703 e4.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  276. 276.

    Chatterjee A, Rodger EJ, Eccles MR. Epigenetic drivers of tumourigenesis and cancer metastasis. Semin Cancer Biol. 2018;51:149–59.

    PubMed  Article  CAS  Google Scholar 

  277. 277.

    Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484–92.

    PubMed  Article  CAS  Google Scholar 

  278. 278.

    Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40(6):741–50.

    PubMed  Article  CAS  Google Scholar 

  279. 279.

    Funato K, Major T, Lewis PW, Allis CD, Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science. 2014;346(6216):1529–33.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  280. 280.

    Lewis PW, Muller MM, Koletsky MS, Cordero F, Lin S, Banaszynski LA, et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013;340(6134):857–61.

    PubMed  PubMed Central  Article  CAS